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ABSTRACT 
Human hepatitis E virus (HEV) was Erst reported in 1980 and is now considered a 
major cause of acute non-A, non-B hepatitis in humans. HEV infection is reported 
throughout the world and occurs in epidemic form in developing countries where the disease 
is endemic and is often associated with water contamination after heavy rains or flooding. 
Sporadic human HEV infections occur in industrialized countries where infected individuals 
contract the infection while traveling to endemic regions. The fecal-oral route is considered 
the primary mode of HEV transmission in humans. HEV infection of pigs was discovered in 
1997. Since 1997, sporadic HEV infections in industrialized countries have been reported in 
people who have not traveled abroad and are associated with HEV isolates genetically 
homologous to those found in domestic pigs. HEV infection of chickens and rats has since 
been documented in the U.S. and abroad. 
Evidence suggests that pigs serve as an important reservoir for HEV and thus 
exposure to pigs, pork products, or pig organs may pose a risk of zoonotic or xenozoonotic 
infection. Swine HEV infection causes a subclinical, non-icteric hepatitis in growing pigs. 
Pigs experimentally-infected with swine HEV had no signs of clinical illness; however, they 
were viremic for 1 to 2 weeks, HEV was present in the liver of infected pigs, and the pigs 
shed a large amount of HEV in feces for several weeks. Similar results were demonstrated 
when pigs were infected with human HEV. We demonstrated that HEV infection of 
pregnant pigs does not induce reproductive failure. We also demonstrated that HEV could be 
transmitted by intravenous exposure of pigs to feces or liver collected from pigs in the early 
stages of infection. We subsequently demonstrated that a high dose and/or repeated exposure 
may be required for fecal-oral transmission of HEV and this is likely to be a common 
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scenario in modem and traditional pig production facilities. HEV also can be detected in pig 
manure storage facilities such as concrete pits and earthen lagoons and we demonstrated that 
HEV found in the pit manure is viable and infectious to pigs. We attempted, but failed, to 
detect HEV in on-site drinking water or surface water on or near pig farms. These findings 
suggest a potential risk of contamination of water supplies by HEV in pig manure exists but 
evidence of this is lacking to date. 
Cross-species infection with HEV among different species of animals has been 
demonstrated; swine HEV infects nonhuman primates, human HEV infects pigs, and chicken 
HEV infects turkeys. Swine and avian HEV have been shown to be genetically distant with 
nucleotide homology of approximately 60%. We demonstrated experimental infection of 
pigs with avian HEV. The avian HEV was found in the liver of inoculated pigs and was shed 
in feces for at least 3 weeks. Rat HEV failed to replicate in pigs. These findings further 
support the growing concern that pigs are an important reservoir of HEV and emphasize the 
critical role of pigs in the epidemiology of HEV. 
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CHAPTER 1. 
GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is prepared as an alternate manuscript format. The dissertation 
includes a general introduction with a hterature review, 5 separate scientific manuscripts, and 
general conclusions. References to hterature cited in the general introduction and the general 
conclusions chapters are listed at the end of the dissertation. Three manuscripts have been 
published in refereed scientific journals relevant to the focus of the dissertation. One 
manuscript has recently been submitted to an appropriate journal. The Ph.D. candidate, 
Chaiyan Kasomdorkbua is the primary author of the manuscripts and is the principal 
investigator for the experimental work described in the manuscripts. The first manuscript 
describes the use of a swine bioassay and an RT-PCR assay to assess the risk of transmission 
of swine hepatitis E virus in pigs and pork products and has been published in the Vbwma/ of 
Fzro/ogzcaZ Mef&odk. The second manuscript describes the experimental infection of 
pregnant gilts with swine hepatitis E virus and has been published in the Cafzadza/z Jbwnza/ of 
Feferzwa?]/ jfesearc/z. The third manuscript describes the routes of transmission of swine 
hepatitis E virus in pigs and has been accepted for publication in the JbwrMaZ of C/zmzcaZ 
Mzcro6zo/ogy. The fourth manuscript describes the presence and infectivity of hepatitis E 
virus in pig manure storage facilities and on-site drinking water and nearby surface water and 
has been submitted to v4#p/zgc? aW .EMvzro/zMze/zfaZ Mzcro6zo/o,gy. The fifth manuscript 
describes experimental evidence for cross-species infection of pigs with avian hepatitis E 
virus. This manuscript will be submitted to the JbwrfzaZ of C/zmca/ Mzcrobzo/ogy. 
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Introduction 
Hepatitis E is an acute hepatitis of humans and is a major public health concern 
worldwide (3, 57, 69, 76). Transmission of HEV is believed to be by the fecal-oral route 
(19). Even though the mortality is generally low and the clinical course of hepatitis E is 
typically self limiting and without a chronic progressive outcome, pregnant women are prone 
to fatal hepatitis E with mortality rates of up to 25% (2,19, 45,48,49). Hepatitis E 
epidemics remain a common public health problem in developing countries in parts of 
Africa, central Asia, and South-east Asia where HEV is endemic and individuals typically 
contract the infection via contaminated drinking water (3. 16, 76). Hepatitis E-associatcd 
disease has been infrequently reported in industrialized countries due to effective sanitation 
measures (8). However, HEV infection in humans living in non-endemic regions has 
recently and increasingly been documented (22, 41, 66, 67, 72, 73, 94, 97). 
Seroepidemiological surveys and genetic analysis of various HEV isolates indicate that there 
may be animal reservoirs such as pigs that serve as an important source for human HEV 
infections (6, 7, 33,42, 81, 84, 93,94, 99). 
Animal strains of HEV have been identified in recent years. Swine HEV was the first 
known animal HEV strain and was discovered in 1997 (61). Avian HEV in chickens was 
identified in 2001 (30). Both swine and avian strains of HEV have been well characterized 
(27,28,29, 38). There is evidence of HEV in rats; however, rat HEV remains to be further 
characterized (20, 31, 33, 42). The prototype swine HEV was first discovered in the United 
States (U.S.) and is genetically closely related to the human strains of HEV found in the U.S. 
(56). Subsequently, other swine strains of HEV have been discovered globally and have 
been found to be ubiquitous in the pig population (7, 23, 33, 37, 57, 58, 59, 61, 86, 88, 94, 
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96). Human and swine HEV that are present in the same countries or geographical regions 
tend to be closely related genetically (36, 61, 62, 66, 81, 91). Based on genomic 
comparisons, the prototype swine HEV is believed to be the ancestral origin of human HEV 
strains found in the U.S. (29) These findings raise concern over the potential risks of pig-to-
human transmission. The concern is strengthened by the Endings that individuals who work 
with swine (i.e. swine veterinarians, pig farmers, or caretakers) are more likely to have anti-
HEV antibodies than non-exposed individuals (17, 56, 58, 96). Furthermore, it has been 
demonstrated that swine HEV infects nonhuman primates and human HEV infects pigs 
experimentally (27, 59, 60). 
Pork is presently a major source of protein for humans. Increasing evidence suggests 
that hepatitis E may also be a fbod-bome zoonotic disease (54, 83, 100). Consumption of 
raw wild boar liver or deer meat has reportedly transmitted HEV to humans (54, 83). Organs 
or tissues collected from swine are also used as xenografts for human patients (102). 
Therefore, the Erst study was designed to assess the risk of transmission of swine 
HEV in pigs by using a swine bioassay and a RT-PCR assay. This experiment used pigs as a 
model to determine if there is a potential risk to transmit swine HEV via liver or pancreas as 
potential xenograft subjects or through pork as a food source. It remains unclear why 
pregnant women with HEV infection frequently develop fulminant hepatitis E with a high 
mortality rate. Pregnant nonhuman primates have been experimentally used as a model to 
investigate the pathophysiology of fulminant HEV infection in pregnant women; however, 
clear answers were not gained from the experiments since characteristics of HEV infection of 
pregnant women were not reproduced in the primate model. Therefore, in the second study, 
a pig model was set up to determine if experimental infection of pregnant gilts with swine 
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HEV may be a suitable model to study the effects of HEV infection during pregnancy and to 
determine if HEV is an important reproductive pathogen in pigs. 
HEV infection induces subclinical hepatitis in growing pigs which exhibit no overt 
clinical signs (27). The natural route (s) of transmission of HEV in pigs is unknown. Since 
pigs may be a source of zoonotic HEV infection in humans, understanding the transmission 
routes of HEV in pigs is needed. Thus, the third study was initiated to investigate possible 
routes of HEV transmission in pigs. Pig manure is stored in large amounts on pig farms and 
is also commonly used as a fertilizer in agricultural practices. Contamination of the 
environment by pig manure is a concern in pig production areas. The fourth study was 
designed to investigate the presence of swine HEV in pig manure storage facilities and 
nearby water sources. A swine bioassay was also included in the study to determine if swine 
HEV found in pig manure or environmental water remained viable and infectious. 
Hepatitis E virus is genetically heterogeneic and geographical clusters of HEV strains 
have been demonstrated (40, 71). HEV discovered in chickens (avian HEV) is genetically 
distant from swine HEV with approximately 60% nucleotide identity compared to over 90% 
identity between the U.S. swine and human HEV (38). It has been shown that avian HEV 
does not cross species barriers to infect nonhuman primates; however, the HEV from 
chickens is still able to infect and replicate in turkeys (38,78). In some parts of the world, 
pigs and chickens are raised in close proximity. It is important to better understand if cross-
species transmission occurs between pigs and chickens and if the virus changes with passage 
in another species. Serologic evidence also indicates the existence of HEV infection in rats 
(21, 33,41). Rats are a potential reservoir for HEV and may also serve as an important 
source for human HEV infection (31). Thus, the fifth study was designed to explore the 
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epidemiology and comparative pathogenesis of HEV infection of pigs with viruses from pigs, 
chickens, and rats. 
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CHAPTER 2. 
LITERATURE REVIEW 
History 
Historically, hepatitis E was associated with what are now thought to be enterically-
transmitted non-A, non-B hepatitis epidemics (69). Hepatitis E associated epidemics were 
reported in the 1950's in India and central Asia (8). The disease was described as a distinct 
viral hepatitis in 1983 following experimental fecal-oral transmission of hepatitis to a human 
who volunteered to orally ingest feces collected from patients with hepatitis A-Iike disease. 
The volunteer developed severe clinical hepatitis and virus-like particles were found in the 
stool collected from the volunteer (5). Since the early 1980's, epidemics of hepatitis E have 
been predominantly reported in developing countries in parts of Africa, central America, and 
Asia. In these areas, HEV-associated disease is thought to be associated with drinking water 
contamination after heavy rains or flooding (16, 47). Hepatitis E has become endemic in 
developing countries where public hygiene is inadequately practiced (8, 75). HEV infection 
is rare in the industrialized countries (8,20). However, sporadic cases of human HEV 
infection are reported in individuals who had a history of traveling to endemic regions (46, 
68). 
Viral Hepatitides in Humans 
Viral hepatitis in humans can be due to infection with a variety of different viruses 
that cause hepatitis and jaundice due to direct or indirect injury to the liver. The human 
hepatitis viral agents comprise five distinct viruses classified in different virus families. 
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Letters from A to E are used to designate each virus based on a chronological manner of the 
discovery of the viruses. 
Hepatitis A vims (HAV) is a major causative agent of acute hepatitis in humans. 
HAV infection is thought to be documented in the Middle Ages during the 8* century AD, 
continued to be a primary infectious problem in the armies during World War H, and remains 
a global health issue (34). In the past, hepatitis A was called "campaign jaundice" or 
"infectious hepatitis". The disease induced by HAV is commonly associated with 
widespread epidemics and is transmitted through the fecal-oral route. HAV is a linear, 
positive-strand RNA and is classified in the family PzcorMovzrzY&ze. The clinical course of 
HAV infection is variable and mild-to-severe in severity. Human patients with acute 
hepatitis A infection typically manifest j aundice due to multifocal inflammatory reactions in 
the affected hepatic parenchyma. Hepatocytes are primarily the site of replication. Young 
children are prone to inapparent HEV infection. Severe clinical hepatitis is typically found in 
a majority of HAV infections in adults. A mortality rate of individuals with clinical hepatitis 
A is low and the infection rarely induces chronic hepatitis. Inactivated or attenuated live 
HAV vaccines are available. 
Hepatitis B virus (HBV) was previously known as "serum hepatitis" since HBV 
epidemics were usually associated with the use of lymph or serum for vaccination and 
transfusion, respectively (35). HBV is a circular, enveloped DNA virus and is classified as a 
/zgpcK&wzvzrwj in the family HBV is a blood-bome agent and the 
transmission is carried out by exposure to blood via blood transfusion, unprotected sexual 
intercourse, parenteral injection and mother-to-infant vertical transmission. The clinical 
course of HBV infection is variable, depending on a variety of host and viral factors. 
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Hepatitis in humans induced by HBV infection can be acute or chronic, and cirrhosis or 
hepatocellular carcinoma may be sequelae in persistent-infected patients. Other animal 
hepadnaviruses have been used as experimental models to study HBV infection at the 
molecular pathogenesis levels. These animal models include woodchuck hepatitis B virus, 
Peking duck hepatitis B virus, and ground squirrel hepatitis B virus. 
Hepatitis C virus (HCV) was previously considered as the sole etiological viral 
agent of non-A, non-B viral hepatitis before HEV was discovered (51). HCV, a member of 
the family F/avmrw&ze, is a linear, positive-sense, single-stranded RNA virus. HCV 
particles are enveloped. Individuals infected with HCV usually develop persistent viremia, 
thus HCV infection is commonly transmitted through exposure to blood by parenteral means 
of drug users. The clinical course of HCV infection is variable, similar to that of HBV 
infection and HCV-infected human patients may exhibit acute or chronic hepatitis. 
Hepatocellular carcinoma and/or cirrhosis are reported as a terminal stage of persistent 
infection in patients with chronic hepatitis C. 
Hepatitis Delta virus (HDV) is a defective virus (24). HDV virions are enveloped 
by the surface antigens of HBV. HDV is a circular, negative-sense, single-stranded RNA 
virus and is classified as a deltavirus without an assigned family. It requires a concurrent 
infection of HBV to induce an acute severe hepatitis in humans, and thus shares the 
parenteral mode of transmission with HBV. HDV-associated hepatitis can be found in 
individuals with a co-infection with HBV or superinfection of a persistent HBV infection. A 
high mortality rate or chronic progressive hepatitis in HDV-infected patients is usually 
associated with coinfections or superinfections of HBV. 
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Hepatitis G virus (HGV) was discovered in 1995 in individuals with fulminant 
hepatitis (77). However, HGV is alternatively known as GB virus type C (GBV-C) and 
currently, GBV-C is preferably used to designate the virus because it has been demonstrated 
to persistently infect humans without acute or chronic clinical hepatitis. GB was named after 
the initials of a patient whose serum was the source of the discovery of the virus. GBV-C is 
a single-stranded RNA virus and is closely related to HCV. GBV-C replicates in 
lymphocytes, but not in hepatocytes, suggesting it may not be a hepatitis agent. Parenteral 
and mother-to-infant transmission has been documented as means of GBV-C infection. 
Interestingly, concurrent infection of GBV-C in humans with human immunodeficiency virus 
(HIV) infection has been found to prolong the survival rate of the patients with acquired 
immunodeficiency syndrome (AIDS). It has been demonstrated that m vzfro coinfection of 
GBV-C and HIV results in diminished HIV replication, thus may provide novel approaches 
for the treatment of HIV infection and AIDS. 
Hepatitis E Virus 
HEV is currently classified as affepevzrwa, a member of family (18). 
HEV is a positive-sense, single-stranded RNA virus. HEV particles are non-enveloped, 
spherical and 27-34 nm in diameter (9,69). The genome of HEV is approximately 7.5 kb in 
length. The genome contains three major open reading frames (ORE); ORF1, ORF2, and 
ORF3. Open reading frame 1 encodes for non-structural proteins exhibiting activities of 
methyltransferase, protease, RNA helicase, and RNA-dependent RNA polymerase (20). 
Open reading frame 2 encodes for structural proteins including a capsid protein. Open 
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reading frame 3 encodes for a cytoskeleton-associated phosphoprotein which is believed to 
play a role in post-replication viral assembly (89, 103). 
Based on analysis of the complete genomic sequence there are 4 major genotypes of 
HEV strains (20). Genotype 1 contains the Burmese strain of human HEV as the prototype 
strain and comprises human HEV strains from Myanmar, India, Japan and South-east Asia. 
Genotype 1 includes the Sar55 strain from which the capsid protein encoded from the ORF2 
region is commonly used as coating antigen for an enzyme immunosorbent linkage assay 
(ELISA) (2, 69). Genotype 2 includes the Mexican strain as the prototype and comprises 
several strains found in Nigeria. Genotype 3 includes the United States HEV and comprises 
the human US-1 and US-2 strains and the prototype swine HEV discovered in the U.S. 
Genotype 4 comprises the newly-identified human and swine HEV strains from Asia and 
Europe (72). The recently-discovered prototype U.S. avian HEV is genetically distant from 
other major genotypes and may represent a new genotype (20, 35). The ORF2 protein of 
avian HEV is genetically quite distant from the HEV strains in the current 4 major genotypes 
but reacts to anti-HEV antibodies against the genotype 1 Sar55 strain of human HEV and to 
genotype 3 swine HEV and US-2 strain of human HEV (28). A recent study of the diversity 
of HEV genomes demonstrated evidence for quasispecies of HEV during human epidemics 
(25). Advance in knowledge at the molecular level of HEV has been hampered by the lack 
of efficient and suitable cell culture systems (19). According to a study of in vitro replication 
of HEV using primate cell lines, HEV has no cytopathic effect, and replication does not 
interfere with host cell division (19). 
In contrast to the genetic heterogeneity of HEV, it appears that HEV strains belong to 
a single serotype (8). Anti-HEV antibodies experimentally induced against one HEV strain 
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are protective against infection by heterologous HEV strains (69). The ORF2 capsid protein 
from the Sar55 strain of human HEV also reacts to naturally-occurring anti-HEV antibodies 
in humans and animals that represent different genotypes (8). 
HEV is a temperature-sensitive, labile virus under laboratory conditions (76). 
Freezing-thawing has been reported to greatly affect the inactivity of HEV (8). However, it 
appears that HEV is relatively resistant to acid and mild alkaline conditions in the intestinal 
tract since a large amount of HEV is shed in feces and the virus remains infectious when the 
feces are used as the source of virus inocula in different animal species models (1,9,27, 52, 
60, 69). HEV was detected in raw sewage collected in the U.S. and European countries 
including Spain and France (15, 67). The HEV detected in raw sewage from Spain remained 
infectious to rhesus monkeys (67). The findings imply that HEV may be stable and viable 
for a certain period of time in variable environments (72). 
Hepatitis E Virus in Humans 
Human hepatitis E infection induces an acute icteric hepatitis (47, 75). The disease is 
typically self limiting. Complete remission is expected without chronic damage to the liver 
(65). Hepatitis E is thought to be transmitted through the fecal-oral route (20). Alternative 
modes of HEV transmission have been reported and include person-to-person, fbod-bome, or 
blood transfusion-associated transmission (14,22, 53, 76). The mortality is generally low 
(0.5 to 3%) in people; however, the mortality in pregnant women with fulminant hepatitis E 
infection may approach 25% (8, 49). Vertical transmission from mother to fetuses also 
occurs (45). 
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Hepatitis E virus infection is common in endemic regions in developing countries and 
is mainly associated with HEV genotypes 1 and 2 (8, 57). Hepatitis E virus infection is rare 
in industrialized countries and is usually reported in patients who have a history of traveling 
to endemic countries (68). However, increasing trends of HEV infection have been reported 
in non-endemic, industrialized countries. Most of these cases are single infections and the 
patient has no history of traveling to endemic areas (22, 53, 72, 73, 97). Although HEV 
infection is infrequent in industrialized countries, HEV may be more widespread than 
previously thought because HEV has been found in human sewage facilities and a high 
prevalence of anti-HEV antibodies has been demonstrated in particular populations (15, 17, 
20, 56, 67, 96). 
Experimental studies in nonhuman primates have been used as models for human 
HEV infection (55, 86, 87, 88). HEV infection in primates is dose dependent (1, 87). 
Primates with clinical HEV infection had increased levels of liver enzymes (alanine 
aminotransferase [ALT] and aspartate aminotransferase [AST]), viral shedding in feces, 
viremia, anti-HEV seroconversion, and necrotizing and lymphocytic hepatitis (55, 74). 
Primates infected with a low titer of HEV may present with subclinical hepatitis (1, 87). In 
subclinical HEV infection, primates shed a large amount of HEV in feces without ALT 
elevation. Delayed anti-HEV antibody responses are also typical of subclinical HEV 
infection (87). 
The pathophysiology of the high mortality present in pregnant women associated with 
fulminant HEV infection remains obscure. There was no evidence of m wfero or perinatal 
infection of offspring borne to pregnant rhesus monkeys infected with human HEV in 
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various stages of pregnancy (86). Fulminant hepatitis E infection was not reproducible in the 
primate model (2, 86). 
Hepatitis E Virus in Pigs 
The first experimental HEV infection in pigs was reported in 1990 (4). Growing pigs 
were inoculated simultaneously via oral and intravenous routes with a human HEV isolate 
that was infectious to rhesus monkeys. The pigs developed severe hepatitis with icterus and 
increased ALT levels and shed HEV virus-like particles in feces. 
The prototype swine HEV was discovered in 1997 in the U.S. (61). In contrast to the 
experimental infection of pigs with human HEV in 1990, natural swine HEV infection did 
not induce clinical hepatitis in pigs (4,61). This Ending was further confirmed by 
experimental infection of pigs with the prototype swine HEV and the US-2 strain of human 
HEV (27). Subsequently, a number of HEV isolates in pigs have been identified and 
characterized throughout the world (6,7,12,23, 36, 81, 91, 93, 101). 
Swine HEV is heterogeneic (40); however, swine and human HEV isolates from the 
same geographical regions form genetic clusters (6, 7, 29, 36, 65, 73, 91). Serologic 
evidence indicates that swine HEV is widespread in pigs (61, 93,101). Furthermore, the 
prevalence of anti-HEV antibodies is higher in people who are exposed to pigs on a regular 
basis (17, 58, 96). 
Direct evidence of the zoonotic potential of HEV emerged on two recent and separate 
occasions. Human HEV infection was found in patients who consumed raw liver from a wild 
boar (54) or raw meat from wild caught deer (93). Comparative analysis of the genetic 
sequences of HEV identified in human hepatitis E patients and in pig livers sold as food in 
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grocery stores provided additional evidence that swine HEV in the liver and human HEV in 
the hepatitis E patients were highly homologous (100). Swine HEV has the ability to cross 
species barriers to infect nonhuman primates based on experimental inoculation (60). A 
human HEV strain has also been shown to infect pigs (27). Therefore, pigs are considered an 
important potential reservoir of HEV. 
Full-length infectious clones of swine HEV have been demonstrated to be effective in 
inducing experimental HEV infection in pigs (37). These infectious clones could be useful 
for studying the molecular mechanism of cross-species transmission and for determining 
zoonotic potential of HEV in a swine model. 
Contamination of the environment with HEV from pig manure is possible (76). 
Organ transplantation using pig organs and/or tissues for human recipients may pose an 
additional risk of xenozoonotic infection of HEV to humans (102). 
Hepatitis E Virus in Chickens 
Hepatitis E virus was identified in chickens in 2001 and designated as avian HEV 
(30). The virus was found in flocks of chickens with hepatitis-splenomegaly syndrome in 
Canada and the U.S. (30, 70). The syndrome affects broiler chickens and laying hens and is 
characterized by high mortality rates and a drop in egg production. Postmortem examination 
of affected chickens generally reveals hepato-splenomegaly, regressive ovaries, and 
serosanguineous abdominal effusion. Histopathological Endings include hepatic necrosis 
and hemorrhage (70). The causative agent (s) responsible for hepatitis-splenomegaly 
syndrome is currently unknown (70) and there is evidence that avian HEV may be the cause 
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of the syndrome (30,79). It was subsequently shown that antibodies to avian HEV were also 
found in healthy chicken flocks (78, 79). 
Avian HEV is comparable morphologically to swine HEV and shares similar 
genomic arrangement composed of 3 ORFs (30, 38). Avian HEV shares antigenic epitopes 
in the ORF2 protein with swine and human HEV. However, avian HEV is genetically distant 
from both human and swine HEV. The nucleotide sequence homology between avian HEV 
and swine HEV is approximately 60%, suggesting that avian HEV may represent a new 
genotype of HEV (38). Avian HEV is heterogeneic (39). Serological surveys indicate that 
avian HEV is enzoonotic in U.S. chicken farms (39,70). Experimental infection of chickens 
with avian HEV demonstrated that avian HEV infection is dose dependent (78). Inoculation 
of chickens with a low titer of avian HEV induced subclinical infection and viremia was not 
detected. However, viremia and virus shedding in feces appeared as early as 1 week 
postinfection in chickens inoculated with a high dose of avian HEV. Antibodies to HEV 
appeared by 4 weeks postinfection and persisted through the termination of the experiment at 
12 weeks postinfection (78). Avian HEV found in chickens is transmissible to turkeys but 
not to rhesus monkeys (38, 78). Chickens and pigs are commonly raised in close proximity. 
It remains to be determined if there is a link between the avian and swine HEV in the 
epidemiology of HEV. 
Hepatitis E Virus in Other Animals 
Naturally-occurring anti-HEV antibodies have been found in a number of domestic 
animal species including pigs, chickens, rodents, cats and cattle (21, 33,41, 76, 84,90). This 
suggests that there may be several natural reservoirs for HEV. Rats are susceptible to 
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experimental HEV infection (52). Anti-HEV antibodies are common in rodent populations 
from different parts of the world (21, 31, 33,42). This suggests that rodents are a potentially 
important reservoir for HEV transmission (31). There is indirect evidence that human HEV 
infection may have originated from the HEV found in domestic rats (31). Rats are also 
widespread on pig and poultry farms. It is important to better understand if there is a 
relationship or interaction between pigs and rats and chickens in regards to HEV 
transmission and epidemiology. 
There is one report indicating that HEV may also be found in wild deer (83). Solid 
experimental evidence does not yet exist to confirm that HEV infects and replicates in wild 
deer. Livers collected from 2 wild deer in the Midwestern U.S. were tested by RT-PCR and 
found to be negative for HEV RNA (C. Kasomdorkbua, unpublished data). The RT-PCR 
used was a universal RT-PCR designed for variant swine HEV isolates (40). Thus, HEV 
RNA in the deer may not have been amplified since the HEV in the deer may have been a 
different genotype, if it exists at all. The role of deer in the epidemiology of HEV awaits 
further investigation. 
Pathogenesis 
Hepatitis E virus replicates in hepatocytes (11, 13, 26, 27, 95). The cytoplasm of 
hepatocytes is likely the site of replication (13, 44). Extrahepatic sites of HEV replication 
also exist and include the small intestines, colon, lymph nodes, tonsil, and spleen (95). The 
liver is considered to be the main source of HEV particles in feces (69). Pigs infected with 
either the U.S. human or swine strains of HEV shed the virus in feces for several weeks 
whereas HEV viremia is transient (27). The HEV genomic RNA has been shown to localize 
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in the cytoplasm of intrahepatic biliary epithelial cells of rhesus monkeys infected with a 
virulent human strain of HEV from Myanmar (44). The detection of HEV RNA by z'/z 
hybridization (ISH) demonstrated that HEV, either a human or swine strain, may replicate in 
the cytoplasm of HEV-infected hepatocytes (13,44). The virions of HEV found in the bile 
may represent those that replicated in hepatocytes and biliary epithelial cells. The newly-
assembled HEV virions may eventually reach the intestinal lumen through the common bile 
duct. It is logical to assume that the epithelial cells along the intestinal mucosa may be 
additional sites for HEV replication outside the liver since the intestines (small intestines and 
colon) have been demonstrated to contain the negative-sense replicative form of HEV 
genome (95). The replication of HEV in the intestinal mucosa may increase the number of 
infectious HEV particles found in pig feces which are believed to be the major source of 
transmission among pigs (26,98). The portal of entry of HEV to the liver remains unknown. 
Entero-hepatic circulation may be a candidate route since HEV antigen was found in the 
mononuclear cells in lamina propia of the intestinal mucosa by ISH (26). The morphology of 
these HEV RNA-positive mononuclear cells was similar to that of lymphocytes and 
macrophages (13). 
The incubation period of HEV in pigs is relatively short (27). Hepatitis E virus RNA 
can be detected in feces as early as 1 week postinfection and shedding in feces persists for 
several weeks. Pigs infected with both human and swine strains of HEV develop anti-HEV 
antibodies following the viremic stage by 2 weeks postinfection and the antibodies persist for 
several months (27, 59, 61). HEV infection in pigs induces hepatitis lesions characterized by 
mild-to-moderate multifocal lymphoplasmacytic infiltrates and focal random hepatocellular 
necrosis by 7 days postinfection (27). HEV RNA has been found in liver, tonsils, lymph 
18 
nodes, spleen, kidney, small intestines, and large intestines from naturally HEV-infected pigs 
by ISH (13). The detection of HEV antigen further confirmed the tissue distribution of HEV 
(26). Among the tissues positive for HEV antigen, liver had the greatest intense and 
extensive amount of staining by immunohistochemistry (IHC). 
It is possible that the inflammatory reaction and the necrosis of hepatocytes in the 
liver are immune-mediated and not the result of direct damage of hepatocytes associated with 
the replication of HEV. HEV antigen was not detected in degenerative hepatocytes 
associated with the hepatitic foci in naturally-HEV-infected pigs by IHC (26). This is in 
agreement with the findings of ISH that did not detect HEV RNA in the cytoplasm of 
degenerative hepatocytes in naturally HEV-infected pigs (13). The associated infiltrating 
lymphocytes were positively stained with markers specific for cytotoxic/suppressor 
properties (74). HEV has been demonstrated to lack cytopathic effect Wfro (19). The 
replication of HEV in primate cell lines showed no destructive effects during cell division 
(19). 
HEV Transmission 
Experimental infection of animals with HEV has been consistently achieved by the 
intravenous route (1, 27,44, 52, 59, 60,74, 78, 86, 87, 88). Oral inoculation is less 
reproducible (55, 69). It has been suggested that swine HEV is naturally transmitted via the 
fecal-oral route (98). However, the fecal-oral transmission of HEV has yet to be confirmed 
under experimental conditions. Serological surveys suggest that HEV spreads rapidly among 
pigs as evidenced by the high prevalence of anti-HEV antibodies in the pig population (12, 
93). An experimental study showed that swine HEV was readily transmitted via direct 
19 
contact (59). Avian HEV was also transmitted to contact chickens under experimental 
conditions (78). More work towards understanding the mode or modes of transmission of 
HEV is needed. 
Diagnosis 
No clinical disease has been associated with natural infection of pigs with HEV in 
the field (40, 61). Experimentally-infected pigs had no evidence of clinical disease (27). 
Current diagnostic methods to confirm HEV infection thus depend on laboratory tests and 
comprise the detection of anti-HEV antibodies in serum samples, HEV RNA in biological 
samples (feces, serum, liver, and bile), and HEV particles by electron microscopy (EM). 
Propagation in cell culture has not yet been successful for use as a diagnostic test or research 
tool (19, 69). 
Currently, the serologic test of choice is an ELIS A (69, 82). Major HEV genotype 
members belong to a single serotype and the antibodies induced by the different HEV strains 
react well with recombinant capsid antigens produced from 2 strains of human HEV (2, 82). 
The coating antigen for the ELISA assay used in swine HEV diagnostics is produced from a 
recombinant capsid antigen of the Sar55 strain of human HEV (27, 61). Specific 
recombinant ORF2 antigen from avian HEV is used for the detection of antibodies specific 
for avian HEV (39). 
Serological diagnosis can be made by the detection of immunoglobulin (Ig) M or IgG. 
The presence of anti-HEV IgM indicates early HEV infection which is important in the 
diagnosis of human infection (2). Anti-HEV IgG has been used primarily on an experimental 
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basis as a marker for experimental HEV infection of swine HEV in pigs and avian HEV in 
chickens. 
HEV RNA can be detected by a nested reverse transcription polymerase chain 
reaction (RT-PCR) assay. Nested RT-PCR is time consuming and costly but is a sensitive 
assay to detect HEV RNA during periods of virus shedding in feces and viremia (27, 59, 60, 
64). HEV viremia is transient (1 to 2 weeks). Pigs shed HEV in feces for several weeks thus 
feces is an appropriate sample for the detection of recent HEV infection in pigs. The primers 
used in the RT-PCR have been designed to specifically amplify HEV strains in pigs or 
chickens. Since HEV, particularly in pigs, is heterogeneic, a universal RT-PCR has been 
developed to amplify all known U.S. swine HEV isolates (40). 
The detection of HEV particles by EM is mainly used for diagnosis of human HEV 
infection. The method is less sensitive than the ELISA and RT-PCR assay because it is 
difficult to detect the virus particles due to the labile nature of HEV in storage (8, 69). 
In primates and humans infected with HEV, elevation of liver-associated enzymes 
including ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), and y-
glutamyl transpeptidase (GGT) can be detected in the serum (1, 9, 41, 46, 55, 83, 87). 
However, experimental infection of pigs with swine HEV was not associated with increase in 
AST, GGT, sorbital dehydrogenase, and total bilirubin during the 35 day duration of the 
study (27). 
Control and Prevention 
Hepatitis E virus is globally ubiquitous in pig populations (8, 93, 98, 99). Subclinical 
infection of HEV in pigs likely accounts for this high prevalence (99). HEV infection tends 
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to spread among a population of pigs as soon as maternal anti-HEV antibodies disappear at 8 
to 9 weeks of age (61). HEV may originate from the older pigs in the same farms since the 
virus is shed in large amounts and for a relatively long period in feces (27, 99). These 
conditions facilitate enzootic infections and constitute the difficulties to control HEV 
infection on pig farms. Constant and strict biosecurity measures may help prevent HEV 
spread. In humans, it is clear that strict and proper public hygiene can prevent HEV 
epidemics in endemic regions. Because HEV is transmitted through the fecal-oral route, the 
primary preventive measures emphasize effective water treatment and proper sewage 
disposal (76). 
Vaccination may be an option to explore to prevent HEV infections. However, a 
major obstacle for the production of killed or attenuated HEV vaccine is the lack of an 
efficient cell culture system for HEV propagation (20, 92). Researchers have investigated 
the use of recombinant subunit or DNA vaccines (50, 92, 104). Commercially available 
vaccines have yet to be developed for humans, pigs, or any other animal species (20, 92). 
An experiment in nonhuman primates demonstrated that anti-HEV antibodies induced 
by a recombinant capsid protein of a virulent HEV strain are protective against a 
heterologous HEV strain (85). In addition, a DNA vaccine expressing the full-length ORF2 
which encodes the HEV structural protein induced anti-HEV antibodies in laboratory mice 
(32). However, challenge infections of susceptible hosts such as nonhuman primates have 
not been performed to confirm vaccine efficacy (32). Recently, cynomolgus monkeys 
vaccinated with a plasmid containing a full-length ORF2 sequence of the Burmese strain of 
human HEV developed anti-HEV antibodies and were protected following challenge 
infection with the Mexican strain of HEV, a virulent human HEV of different genotype (43). 
22 
In these experiments, intradermal or intramuscular routes were used. Oral vaccination using 
a recombinant capsid protein of HEV expressed in the baculovirus expression system was 
shown to induce effective protection against HEV infection in cynomolgus monkeys (50). 
Experiments on vaccine development for protection against HEV infection show promising 
results; however, the information regarding the duration of acquired protective anti-HEV 
antibodies is limited (104). The effectiveness of these vaccines awaits trials in humans. 
Passive immunization with anti-HEV IgG antibodies has been proposed in individuals at risk 
of HEV infection such as pregnant women or tourists traveling to endemic regions (10, 69). 
However, passive immunization failed to protect against experimental HEV infection in 
nonhuman primates (10). No control or eradication measures have currently been attempted 
to date in pigs, chickens, or other animals. 
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CHAPTER 3. 
USE OF A SWINE BIO ASSAY AND A RT-PCR ASSAY TO 
ASSESS THE RISK OF TRANSMISSION OF 
SWINE HEPATITIS E VIRUS IN PIGS 
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Denis K. Guenette, Thomas E. Toth, and Xiang-Jin Meng 
Abstract 
The objective of this study was to assess the risk of transmission of swine hepatitis E 
virus (swine HEV) to naïve pigs by inoculation with tissues or feces collected from pigs 
experimentally infected with swine HEV. Seventy-five, 3-week-old pigs were randomly 
assigned to 24 groups of 3-4 pigs and inoculated with homogenates of tissues (liver, heart, 
pancreas, or skeletal muscle) or a suspension of feces from swine HEV-infected pigs 
collected at 3, 7, 14, 20, 27, or 55 days post inoculation (DPI). Each inoculum was prepared 
as a 10% suspension (W/V) in PBS buffer and tested by a semi-quantitative RT-PCR for 
swine HEV RNA and by the swine bioassay. The inoculation route was intravenous for 
liver, heart, and pancreas and via stomach tube for skeletal muscle and fecal suspension. 
The liver homogenate inocula and feces collected at 3-7 DPI and 14-20 DPI were positive 
for swine HEV RNA by RT-PCR. The pigs inoculated with liver homogenates collected at 
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3-7 DPI and 14-20 DPI developed anti-HEV antibodies and swine HEV RNA was detected 
in their sera. Pigs inoculated with heart, pancreas, skeletal muscle homogenates or fecal 
suspensions failed to develop anti-HEV antibodies. These findings suggest that there is a 
potential risk of transmission of swine HEV via liver tissue from infected pigs in the early 
stages (3-20 DPI) of infection and the in vitro RT-PCR assay correlates well with the swine 
bioassay. 
.Keywords/ Swine hepatitis E virus; HEV; swine bioassay; RT-PCR; Pig 
1. Introduction 
Hepatitis E virus (HEV) is a non-enveloped, single-stranded, positive sense RNA 
virus and is the causative agent of acute hepatitis E (Purcell, 1996). HEV was classified 
originally in the family Ca/fcmnJag (Purcell, 1996; Reyes, 1997), but was subsequently 
declassified and designated in an unassigned genus "hepatitis E-like virus" (Pringle, 1998). 
The disease is considered to be endemic in many developing countries in Asia, Africa and 
Mexico where the disease usually occurs as epidemics. The natural transmission of HEV is 
generally believed to be fecal-oral by contamination of drinking water following heavy rains 
or flooding (Krawczynski, 1993). Sporadic cases of HEV infection have also been reported 
in industrialized countries such as the United States and European countries where the 
disease is generally considered as non-endemic and the occurrences are usually associated 
with travel to endemic countries (Dawson et al., 1992; Herrera et al., 1993; de Groen et al., 
1997). Recent cases of hepatitis E infection without a history of travelling to endemic 
regions have been confirmed in industrialized countries (Schlauder et al., 1998; Schlauder et 
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al., 1999; Worm et al., 2000). In addition, an isolate of HEV from a pig, designated as a 
swine HEV, has been identified and shown to be closely related to the two human isolates of 
HEV (US-1 and US-2) identified in the United States (Meng et al., 1997). Analysis of open 
reading frames 1 and 2 of the US-1 and US-2 human isolates and swine HEV revealed a 
relatively high amino acid identity, up to 97% (Meng et al., 1998b). Similar findings have 
also been reported in pigs from Taiwan with a different strain of swine HEV (Hsieh et al., 
1999). Experimental cross species infection has been demonstrated. Swine HEV has been 
shown to infect rhesus monkeys and a chimpanzee, and the US-2 strain of human HEV has 
been shown to infect pigs (Meng et. al., 1998a; Halbur et al., 2001). These findings suggest 
that swine may be an animal reservoir and thus raises a concern of HEV as a potential 
zoonotic agent (Meng, 2000b; Piper-Jenks et al., 2000). 
Seroepidemiological studies of HEV in both endemic and non-endemic regions have 
shown that anti-HEV antibodies are present in domestic animal species including pigs and 
captured wild rats (Kabrane-Lazizi et al., 1999; Meng et al., 1999; Favorov, et al., 2000). 
Pigs as the donor animal species for xenotransplantation have received considerable attention 
since they are easy to breed, economical to produce, and similar in their physiology and size 
of organs to humans. Pig liver, pancreatic islets, and heart/valves have been used as 
organ/tissue for human xenotransplant recipients (Leventhal et al., 1993; Butler, 1998; Yoo 
and Giulivi, 2000). Xenotransplant procedures which allow pathogenic organism to bypass 
human defense mechanism due to the immunocompromised condition in human xenograft 
recipients, would affect the virulence of pathogenic or non-pathogenic agents (Yoo and 
Giulivi, 2000). A recent study of the experimental infection of swine HEV and the US-2 
strain of human HEV in pigs has shown that both strains can infect and replicate in pigs and 
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the virus was detected in the liver and bile and was also shed in feces (Halbur et al., 2001). 
Therefore, it is important to assess the risk of transmission of HEV to naive pigs by 
inoculation with tissues and feces prepared from known HEV-infected pigs and to evaluate 
whether or not an in vitro semi-quantitative RT-PCR assay correlates with an in vivo swine 
bioassay in detecting swine HEV infection. The study was designed to determine if there is a 
risk of HEV transmission by skeletal muscle tissue via oral inoculation (in an effort to mimic 
consumption of undercooked pork meat) or by intravenous inoculation of liver or heart or 
pancreas (to mimic organ/cell transplantation) from HEV-infected pigs to xenograft 
recipients using a swine model. 
2. Materials and Methods 
2.1. vdmTMaZs 
Seventy-five, 2-week-old, specific-pathogen-free (SPF) pigs (.Swa acrq/h cbmesfzcHj) 
were purchased from a commercial farm. All pigs were tested by ELISA assay for swine 
HEV IgG antibodies. Only seronegative pigs were used for inoculation. The pigs were 
allowed to acclimate to the research facilities for 1 week prior to inoculation. 
2.2 /MOCK&Z 
The inocula were prepared from tissues (liver, heart, pancreas, or skeletal muscle) and 
feces of SPF pigs experimentally infected with swine HEV from a previous study (Halbur et. 
al., 2001). Tissues or feces collected at 3 and 7 (3-7), 14 and 20 (14-20), and 27 and 55 (27-
55) DPI from HEV-infected pigs were pooled respectively, and used to make the inocula. 
All tissues and feces were stored at -70°C from the time of necropsy until they were prepared 
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as inocula. Each inoculum was prepared as a 10% tissue homogenate (w/v) or a 10% 
suspension of feces (w/v) in PBS buffer (Table 1). All inocula were stored at -70°C until 
used for inoculation. Each inoculum was tested by a semi-quantitative RT-PCR for swine 
HEV RNA (see below). The positive control inoculum was a standard infectious pool of 
swine feces with a 10^ 50 % pig infectious dose (PID50) of swine HEV per ml (Meng et al., 
1998b). 
2.3 Defecfzo» amd je/MZ-gwaM&'fafn'g fzfrafzoM ofywme HEF/UV/i mocw/a aW aero 
RT-PCR was carried out essentially as described previously (Meng et al., 1998a, 
1998b). Briefly, total RNA was extracted from 100 ^1 of each sample (10% fecal suspension 
or tissue homogenates) by TriZol reagent (GIBCO/BRL, Gaithersburg, MD). All samples 
were tested by a nested PCR with primers located in the putative capsid gene (ORF2) (Meng 
et al., 1998a, 1998b). The first round PCR produced an expected fragment of 404 base pairs 
with the forward primer F1 (5'-AGCTCCTGTACCTGATGTTGACTC-3') and the reverse 
primer R1 (5'-CTACAGAGCGCCAGCCTTGATTGC-3'). For the second round PCR, the 
forward primer F2 (5'-GCTCACGTCATCTGTCGCTGCTGG-3') and the reverse primer R2 
(5 ' -GGGCTGAACC AAAATCCT G AC AT C-3 ') produced an expected fragment of 266 base 
pairs. Total RNA was reverse transcribed with R1 reverse primer and SuperScript II reverse 
transcriptase (GIBCO/BRL) at 42 °C for 1 hour. The resulting cDNA was amplified by PCR 
with ampliTaç Gold DNA polymerase. The PCR reaction was carried out for 39 cycles of 
denaturation at 94 °C for 1 minute, annealing at 52 °C for 1 minute, extension at 72 °C for 1.5 
minutes, and followed by a final incubation at 72 °C for 7 minutes. The second round PCR 
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reactions were performed with similar parameters as above with 10 pi of the first round PCR 
mixture as the template. The amplified PCR products were examined by gel electrophoresis. 
The virus titer of inocula was calculated and expressed as genome equivalent (GE) per ml of 
sample (Meng et al., 1998a, 1998b). Our previous studies showed that viremia in swine 
HEV infected pigs generally occurred from 7 to 20 DPI (Halbur et al., 2001; Williams et al., 
2001). Therefore, serum samples of inoculated pigs collected from 7 to 21 DPI were also 
tested by RT-PCR for swine HEV RNA. 
2.4 i&perz/Mefz&zZ znocw&zfzo/z ofaW eva/wafzom of c/zfzzcaZ szgrz,? and /eszoMj 
Seventy-five pigs were randomly assigned into 24 groups of 3-4 pigs and inoculated 
with different inocula (Table 1). Each group of pigs was housed in a separate room. All pigs 
were allowed access to food ad libitum. The inoculation route was intravenous for 
homogenates of liver, heart, and pancreas to mimic xenotransplant procedures. Homogenates 
of skeletal muscle and fiscal suspensions were inoculated orally via stomach tube to 
determine if there is a risk of swine HEV transmission by consumption of undercooked pork 
meat or by drinking feces-contaminated water. Homogenates of tissues and suspensions of 
feces collected from normal SPF pigs served as negative controls and a group of 3 pigs 
served as uninoculated controls. For positive controls, 3 groups of pigs were inoculated with 
a 10^ PID#, approximately equivalent to 10* GE, of swine HEV via oral drop, stomach tube, 
or intravenous route, respectively. 
Clinical signs were monitored daily until the end of the experiment at 56 DPI. Serum 
samples were collected weekly for testing for the presence of anti-HEV antibodies by ELISA 
assay. Pigs were necropsied at the end of the experiment at 56 DPI. Tissues collected from 
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major organs including liver, gall bladder, small intestines, colon, lymph nodes, spleen, 
tonsil, heart/heart valves, kidney, and lung were processed by routine procedure for 
examination for histopathologic changes by hematoxylin & eosin staining. 
2 J. Defecfzorz of a/iA-f/EFaerwrn a/zfz6o<#g,s 
A standardized ELISA was used to detect anti-HEV IgG antibodies in swine sera. 
Serum samples were tested prior to inoculation and weekly throughout the study. The 
ELISA for anti-HEV antibodies in swine was performed essentially as described (Meng et 
al., 1997,1998a, b). A purified 55-kDa truncated recombinant putative capsid protein of 
human HEV strain Sar-55 was used as the antigen. This antigen cross-reacts well with the 
swine HEV. Peroxidase-labeled goat anti-swine IgG (Kirkgaard & Perry Laboratories, 
Gaithersburg, MD) was used as the secondary antibody. All serum samples were tested in 
duplicate. Preimmune and hyperimmune anti-HEV -positive swine sera were included as 
negative and positive controls, respectively. 
3. Results 
3.7. Defecfzo/i of-swmg HETm mocwAz a sgmz-gwanfzfafn'g 
Swine HEV RNA was detected in the inocula of hver homogenates and feces 
collected at 3-7 DPI and 14-20 DPI (Table 1). The virus titer of the inocula of liver 
homogenates collected at 3-7 DPI and 14-20 DPI was approximately 10* GE/ml and 1CP 
GE/ml, respectively. The virus titer for the 3-7 DPI and 14-20 DPI feces inocula was 
approximately 10^ GE/ml. None of the other inocula of tissue homogenates prepared from 
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heart, pancreas, or skeletal muscle contained detectable swine HEV RNA. The virus titer of 
the inocula of swine HEV infectious pool was approximately 10* GE/ml. 
There were no clinical signs in any pigs of any group. Gross and microscopic lesions 
were unremarkable in pigs necropsied at the end of the experiment (56 DPI). 
Seroconversion to anti-HEV antibodies was used to monitor swine HEV infection in 
inoculated pigs in this swine bioassay. The positive control pigs inoculated intravenously 
and the pigs inoculated with liver homogenates collected at 3-7 and 14-20 days post 
inoculation developed anti-HEV serum antibodies between 3 to 8 weeks post inoculation 
(Table 1). In the positive control group, only pigs inoculated intravenously seroconverted: 
one pig became seropositive at 21 days post inoculation and the other two at 28 days post 
inoculation. Pigs in the other two positive control groups (inoculated orally or via stomach 
tube) remained seronegative at the end of the study. Pigs in the liver homogenate groups 
seroconverted between 21 and 35 DPI. Pigs in the 27-55 DPI liver inocula group remained 
seronegative in the swine bioassay. The 27-55 DPI liver inocula were negative by RT-PCR 
assay. The 3-7 and 14-20 DPI feces inocula tested positive by RT-PCR assay, but results 
from the swine bioassay were negative when inoculation was done via stomach tube route. 
All the other groups remained seronegative through the end of the study at 8 weeks post 
inoculation (Table 1). 
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We have previously shown that pigs typically are viremic &om 7 to 20 DPI and that 
seroconversion to HEV antibody is a reliable indicator of swine HEV infection (Halbur et al., 
2001). Serum samples collected between 7 to 21 DPI from selected groups (all nine pigs 
inoculated with swine HEV infectious pool, all nine pigs inoculated with liver homogenate, 
and all nine pigs inoculated with fecal suspension) were tested by RT-PCR. All but one of 
the pigs that seroconverted to HEV were also positive for swine HEV RNA in sera by RT-
PCR (Table 1). The seropositive pig that was negative for HEV RNA (during 7 to 21 DPI) 
was from the group intravenously inoculated with the swine HEV infectious pool. There was 
one pig inoculated with the 14-20 DPI liver homogenate that was positive for HEV RNA at 
14 DPI and remained seronegative through 56 DPI. 
4. Discussion 
Xenotransplantation with swine organs and tissues can potentially offer an alternate 
solution to the shortage of transplantable human organs. However, xenozoonosis, the 
inadvertant transmission of swine pathogens from pigs to human xenograft recipients, is of 
major concern. Previous studies have shown that swine HEV appears to be ubiquitous in 
pigs, and can infect across species barriers (Meng et al., 1997, 1998a, b, 1999; Meng, 2000a, 
b; Halbur et al., 2001). Thus, transmission of swine HEV from pig tissues/organs to human 
xenograft recipients and the potential subsequent transmission of the virus to others such as 
family members and healthcare workers is possible (Meng, 2000a, b). Since hepatitis E virus 
is most likely transmitted fecal-orally, there is also growing concern about the possibility of 
contracting the disease by consuming undercooked pork meat or by drinking swine feces-
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contaminated water. Therefore, the objectives of this study were to assess the risks of 
transmitting swine HEV from infected pigs to naïve pigs and to evaluate the usefulness of an 
in vitro RT-PCR assay in detecting swine HEV as compared to an in vivo swine bioassay. 
The routes of inoculation varied in order to mimic the procedures in 
xenotransplantation (intravenous), meat consumption (oral), and natural transmission 
(presumably fecal-oral route). Intravenous inoculation (with feces and liver tissue) was 
successful, but oral inoculation (with feces and muscle tissue) was not successful in 
transmission of HEV in this study. Feces and hver tissue were collected from the same pigs, 
and the liver (with a titer of 10^ - l(f GE/ml) was determined to be infectious when 
inoculated intravenously, whereas the feces (with a titer of 1(P GE/ml) were not infectious 
when inoculated orally. Even our standard infectious pool (swine feces) of HEV with a titer 
of 10* GE/ml was not adequate to induce infection orally. This observation is consistent with 
earlier studies with hepatitis A and E viruses in non-human primates (Purcell et al., 
unpublished). The results suggest that HEV transmission via fecal-oral route requires a much 
higher dose compared to the intravenous route of transmission. It also suggests that the 
likelihood of transmitting HEV via consumption of pork from an HEV infected pig is 
minimal. 
It remains unknown how HEV is transmitted under natural conditions. Transmission 
apparently occurs easily since serological surveys indicate that HEV is ubiquitous in the 
swine population (Meng et al., 1997; Meng et al., 1999). Previously, it was demonstrated 
that transmission of HEV by contact exposure of experimentally inoculated pigs with a naïve 
pig (Meng et al., 1998a). It has also been reported that 8-10 kg pigs were susceptible to 
experimental infection with a strain of HEV isolated from a human patient's stool via 
simultaneous intravenous and oral routes (Balayan et al., 1990). 
Many factors may influence the infectivity of HEV infection such as the virus titer, 
the ratio of infectious to defective viral particles, the inoculation routes, and host factors such 
as immune status and age at exposure (McCaustland et al., 2000). Our results confirm that 
virus titer and the routes of inoculation are important for HEV transmission. Host mucosal 
immunity in the alimentary tract could play a role in diminishing the infectivity of swine 
HEV via oral inoculation (oral drop or stomach tube). It is possible that IgA could attribute 
to immune exclusion of the virus on mucosal surfaces (Tizard, 2000; Bourne et. al., 1978). 
Thus, intravenous inoculation would allow the virus in the inocula to avoid the effect of this 
host defense mechanism. It remains unclear whether the portal of entry of the virus is via the 
alimentary tract and if the intestines serve as the initial site of replication before the virus 
reaches the liver. A recent study suggests that HEV replicates extrahepatically, as negative-
strand viral RNA was detected in the small intestines, spleen, lymph node, and tonsil 
(Williams et al., 2001). 
Due to the lack of a suitable cell culture for HEV propagation, the infectivity of HEV 
can not be determined in vitro. In this study, we attempted to see if a RT-PCR assay could 
be used to screen swine HEV infectivity in vivo. The findings from the study indicated that 
the results of inocula tested by RT-PCR assay correlates well with the swine bioassay if the 
inoculation route was performed intravenously. The inocula tested positive by RT-PCR were 
infectious in pigs in the swine bioassay via intravenous route, whereas the inocula tested 
negative by RT-PCR failed to induce seroconversion in the swine bioassay. The data 
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suggested that RT-PCR assay could be used to detect the presence of swine HEV in pig 
tissues. 
Detection of anti-HEV seroconversion appears to be a reliable indicator for both 
swine and human HEV infection in experimentally inoculated pigs (Halbur et al., 2001). 
There was one seropositive pig (in the swine HEV infectious pool group) in the current study 
from which we were unable to detect viremia between 7 and 21 DPI. It has been reported 
that HEV viremia may be undetectable until 42 days post-inoculation (Meng et al., 1998a) 
which may be the case with this pig. There also was one viremic pig that remained 
seronegative in this study. This pig (inoculated with the 14-20 DPI liver homogenate) might 
have seroconverted had we allowed the pig to hve longer since antibodies may require longer 
than 56 days to reach detectable levels (Meng et al., 1997; Meng et al., 1998a). 
All inoculated pigs remained clinically normal. Since the scope of this study was to 
determine transmissibility of HEV, we measured seroconversion to HEV in all pigs and 
performed RT-PCR on sera on selected groups for evidence of virus infection. The pigs all 
necropsied at the end of this 56-day study had no remarkable gross or microscopic lesions in 
the liver. This is consistent with our earlier studies showing that swine HEV induced 
hepatitis lesions that were detectable during the early stages of infection (3 to 20 days post 
inoculation). The hver lesions were subtle or nearly resolved by 55 days post inoculation in 
pigs experimentally infected with swine HEV in a previous study (Halbur et al., 2001). 
In summary, it was demonstrated that swine HEV can be transmitted to 3-week-old 
naive pigs via homogenates of liver from infected pigs in the early stages of disease. 
Therefore, xenotransplantation with swine HEV-infected pig livers would be a potential 
source for transmitting the virus to human patients. Other tissues including heart and 
pancreas seem to be an unlikely source of swine HEV transmission since the RT-PCR assay 
was unable to detect swine HEV RNA in those tissues and their inocula also failed to induce 
seroconversion in the swine bioassay. The data also indicated that there is a minimal risk of 
transmission of swine HEV by skeletal muscle homogenates. The correlation between the in 
vitro RT-PCR assay and the in vivo swine bioassay results suggests that RT-PCR may be 
used as a screening tool for detecting the presence of swine HEV in potential xenograft donor 
pigs or pig tissues. 
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Table 1. Risk assessment of transmitting swine HEV from infected pigs to naive pigs: results 
of RT-PCR assay and swine bioassay. 
Inocula Inoculation Route Inocula Titer 
by RT-PCR (GE/ml) 
Seroconversion * HEV RNA 
in serum6 
None Uninoculated N/A° 0/3 NT" 
Swine HEV infectious pool Oral drop IQk 0/3 0/3 
Swine HEV infectious pool Stomach tube 10* 0/3 0/3 
Swine HEV infectious pool IV 10* 3/3 2/3 
Negative control live/ IV Negative 0/3 NT 
3-7 DPI liver IV 10' 2/3 2/3 
14-20 DPI liver IV l(f 2/3 3/3 
27-55 DPI liver IV Negative 0/3 0/3 
Negative control fecesf Stomach tube Negative 0/3 NT 
3-7 DPI feces Stomach tube l(f 0/3 0/3 
14-20 DPI feces Stomach tube 10^ 0/3 0/3 
27-55 DPI feces Stomach tube Negative 0/3 0/3 
Negative control hear/ IV Negative 0/3 NT 
3-7 DPI heart IV Negative 0/4 NT 
14-20 DPI heart IV Negative 0/3 NT 
27-55 DPI heart IV Negative 0/3 NT 
Negative control pancreas1 IV Negative 0/3 NT 
3-7 DPI pancreas IV Negative 0/4 NT 
14-20 DPI pancreas IV Negative 0/4 NT 
27-55 DPI pancreas IV Negative 0/3 NT 
Negative control muscle1 Stomach tube Negative 0/3 NT 
3-7 DPI muscle Stomach tube Negative 0/3 NT 
14-20 DPI muscle Stomach tube Negative 0/3 NT 
27-55 DPI muscle Stomach tube Negative 0/3 NT 
"Anti HEV antibodies detected by ELISA, number positive pigs/number tested. 
^ Serum samples tested by RT-PCR at 7, 14, and 21 DPI, number positive pigs/number tested. 
"Not applicable. 
^ Samples not tested. 
'Approximately equivalent to 10^ PID* 
^Negative control tissues and feces were collected from normal SPF pigs that were negative for swine HEV. 
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CHAPTER 4. 
EXPERIMENTAL INFECTION OF PREGNANT GILTS 
WITH SWINE HEPATITIS E VIRUS 
A paper published in 
TTze Canal##» JowmaZ ofFeferzfKzry Tf&searcA 67:303-306, 2003. 
Chaiyan Kasomdorkbua, Brad J. Thacker, Patrick G. Halbur, Denis K. Guenette, 
Ryan M. Buitenwerf, Ryan L. Royer, and Xiang-Jin Meng 
Abstract 
To determine the effect of swine hepatitis E virus (HEV) infection on pregnant gilts, 
their fetuses, and offspring, 12 gilts were intravenously inoculated with swine HEV. Six gilts, 
who were not inoculated, served as controls. All inoculated gilts became actively infected 
and shed HEV in feces, but vertical transmission was not detected in the fetuses. There was 
no evidence of clinical disease in the gilts or their offspring. Mild multifocal 
lymphohistiocytic hepatitis was observed in 4 of 12 inoculated gilts. There was no 
significant effect of swine HEV on fetal size, fetal viability, or offspring birth weight or 
weight gain. The offspring acquired anti-HEV colostral antibodies but remained seronegative 
after the antibodies waned by 71 days of age. Swine HEV infection induced subclinical 
hepatitis in pregnant gilts, but had no effect on the gilts' reproductive performance, or the 
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fetuses or offspring. Fulminant hepatitis associated with HEV infection was not reproduced 
in gilts. 
Summary of short communication 
Human hepatitis E virus (HEV) is the causative agent of acute non-A, non-B, and 
icterus-inducing hepatitis in humans and is characterized as a non-enveloped, single-
stranded, positive sense RNA virus (1). Hepatitis E virus is considered to be enterically 
transmitted via the fecal-oral route. Swine HEV, first isolated from a pig in Illinois, is closely 
related to two human isolates of HEV (US-1 and US-2) identified in the United States (U.S.) 
(2). Cross species infection has been experimentally demonstrated; swine HEV infected 
rhesus monkeys and a chimpanzee, and the US-2 strain of human HEV infected pigs (3, 4). 
These findings infer that swine may be an animal reservoir for HEV, raising concern that 
HEV is a potential zoonotic or xenozoonotic agent (5). Swine HEV is reportedly ubiquitous 
in the U.S. swine population (2). Furthermore, occupational exposure to swine such as with 
swine farmers or veterinarians poses a higher risk of HEV infection among these individuals, 
suggesting the possibility of animal-to-human transmission (6, 7). 
The course of hepatitis E in humans is self-limiting and chronic illness is not 
observed (1). Overall case mortality is low, ranging from 0.2% to 4%, although high 
mortality rates of 10% to 25% have been reported in pregnant women suffering from 
fulminant hepatitis associated with HEV. This particular presentation of hepatitis E mostly 
occurs in the third trimester of pregnancy (8, 9). Explanation for this phenomenon is still 
obscure. Vertical transmission of HEV via intrauterine infection was suggested as HEV RNA 
was detected in cord blood samples from infants bom to mothers affected with acute 
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fulminant hepatitis (10,11). Accordingly, an animal model would be useful to further the 
understanding of HEV-induced fulminant hepatitis in pregnant women. Non-human primates 
(cynomolgus macaques, chimpanzees and rhesus monkeys) are susceptible to HEV infection 
and have been widely used in experimental models (4,12). However, pregnant rhesus 
monkeys inoculated intravenously with human HEV strain SAR.-55 from Pakistan did not 
exhibit the characteristics of the fulminant hepatitis disease as seen in pregnant women. 
Neither a fatal effect of HEV infection on the mother or the fetuses, nor neonatal infection, 
was found in the study (3). 
Since the discovery of swine HEV, experimental studies of swine HEV infection in 
growing pigs have been well described (3). Lack of an animal model for reproducing 
fulminant hepatitis E in pregnant women and the need for information regarding the effect of 
HEV infection in pregnant swine prompted us to investigate the effect of swine HEV 
infection in pregnant gilts during late gestation on dams, fetuses and offspring, and to 
determine if the disease pattern of fulminant hepatitis E in pregnant women can be 
reproduced in pregnant swine. 
Eighteen swine HEV-seronegative gilts (Swa acro/â &w»asficwa), originating from the 
Iowa State University speciGc-pathogen-free herd were used and randomly assigned to swine 
HEV-inoculated group (n-12) or sham-inoculated control group (n=6). The experimental 
procedures were reviewed and approved by the Iowa State University Committee on Animal 
Care. The swine HEV inocula contained a titer of 10^ 50% pig infectious dose (PIDgo) per 
mL, which was equal to the titer used in a previous experimental infection of swine HEV 
study in growing pigs (3). Twelve gilts were intravenously inoculated via an ear vein at 78 to 
80 d of gestation. Clinical observations (appetite, lethargy, icterus, or diarrhea) were 
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conducted daily throughout the study and gilt rectal temperatures were measured for 14 d 
after inoculation. Five to 6 gilts (4 inoculated and 1 or 2 controls) were euthanized by 
intravenous administration of an overdose of sodium pentobarbital on 3 separate days as 
follows; 91 d of gestation (12 d post inoculation [DPI], 1 control and 4 inoculated) 105 d of 
gestation (26 DPI; 2 controls and 4 inoculated), or at 17 to 19 d after farrowing (55 DPI; 2 
controls and 4 inoculated). One control gilt that had gone into estrus again at 21 d post-
service and was reserviced immediately, was necropsied at 46 DPI or 81 d of gestation. 
Four, 8- to 10-day-old piglets from each of the 6 sows that farrowed were necropsied at 46 
DPI. Gross examination of the reproductive tract and internal organs of the gilts and 
offspring was performed. At necropsy, the number of fetuses, fetal viability and condition, 
fetal weight, and fetal crown-rump length were recorded. A set of tissues including liver, gall 
bladder, uterus, ovary, salivary gland, duodenum, jejunum, ileum, colon, pancreas, tonsil, 
spleen, lymph nodes, heart, skeletal muscle, lung, and kidney were collected from each gilt 
for microscopic examination, using hematoxylin and eosin staining. A set of tissues collected 
from each pig included liver, brain, thymus, tonsil, spleen, lymph nodes, lung, kidney, heart, 
duodenum, jejunum, ileum, and colon. The same types of tissues (excluding lymph nodes) as 
collected from the pigs, plus the umbilical cord, were collected from fetuses for microscopic 
evaluation. Offspring were weighted at birth and periodically thereafter to evaluate weight 
gain. All surviving pigs were weaned at 18 d of age and pigs from control gilts were mixed 
with those from inoculated gilts. Blood samples from these pigs were periodically collected 
for HEV serology until 102 d of age. 
Blood samples were collected from the gilts prior to and throughout the study for 
HEV serology, HEV RNA detection by a nested reverse transcriptase-polymerase chain 
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reaction (RT-PCR) assay, and liver chemistry profile (alkaline phosphatase, aspartate 
aminotransferase, gamma-ghitamyl transferase, sorbitol dehydrogenase, and total bilirubin) 
by an automated analyzer (Hitachi 912; Roche, Indianapolis, Indiana, USA). Fecal samples 
were also collected at the same time to be tested for HEV RNA by RT-PCR. Overall, 
samples for RT-PCR testing included serum, feces, liver tissues, and bile obtained from the 
gilts, and serum and pooled tissues (liver, lung, kidney, spleen, and small intestines) obtained 
from 2 fetuses (both normal or one normal and one mummified fetus with crown-rump length 
more than 15 cm.) per litter. A nested RT-PCR technique was performed as previously 
described (3). The enzyme linked immunosorbent assay (ELISA) for swine anti-HEV 
antibodies was performed as previously documented (2). The cut-off absorbance value used 
for positive samples was 0.3. 
A commercial software package was used to perform statistical analyses (Statistic, 
version 4.0; Analytical software, Tallahassee, Florida, USA). Proportional reproductive data 
were tested by Fisher's exact test (proportion of normal, small, stillborn or mummified 
fetuses/pigs). Other data (rectal temperatures, liver chemistry profile values, fetal weight and 
length, offspring birth weight, and weight gain and litter size) were calculated as mean ± 
standard deviation (s). Data were tested for statistical difference between inoculated and 
control groups by using an analysis of variance (ANOVA). For all analyses, values off < 
0.05 were considered significant. 
There were no clinical signs or fever observed in the inoculated gilts or their piglets 
(data not shown). Liver chemistry profile values were no different between inoculated and 
control gilts (data not shown). There were no significant differences between inoculated and 
control groups with regard to fetal weight and length, or offspring birth weight and weight 
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gain (data not shown). None of the reproductive parameters from inoculated gilts were 
significantly different from control gilts (Table I). Although, the percentage of mummified 
fetuses in inoculated gilts was higher than control gilts, based on crown-rump length, the 
majority of these fetuses died prior to inoculation. Overall, litter size was relatively high for 
gilts and at necropsy many of the mummified fetuses were clustered together in one segment 
of the uterus, suggesting that fetal death occurred due to intra-uterine crowding. There were 
no significant gross lesions in any of the gilts, fetuses or piglets. Mild multifocal 
lymphohistiocytic hepatitis associated with occasional individual hepatocyte necrosis was 
found in 4 of 12 inoculated gilts. Four inoculated gilts (including 2 of the gilts with hepatitis 
lesions) had mild multifocal lymphohistiocytic interstitial nephritis. There were no 
remarkable microscopic lesions in any tissues obtained from piglets or fetuses. 
All except 1 of the inoculated gilts (7 of 8 gilts) seroconverted to anti-HEV by 19 
DPI. Four inoculated gilts were necropsied at 12 DPI, hence their serum samples were not 
available for ELISA testing thereafter. All 8 remaining gilts subsequently acquired anti-HEV 
antibodies by 26 DPI and all 4 gilts that were allowed to farrow continued to be seropositive 
through to 47 DPI. All control gilts remained seronegative throughout the study. Detectable 
HEV antibodies were found in pigs from HEV-inoculated dams, when first samples at 10 d 
of age. A proportion of the pigs continued to be seropositive until 61 d of age and all pigs 
were seronegative thereafter (102 d of age) (Table H). Results of the RT-PCR of samples 
obtained from swine HEV-inoculated gilts and their fetuses are summarized in Table HI. All 
samples obtained from control gilts and their fetuses contained no detectable level of swine 
HEV RNA. Since experimental swine HEV infection is readily detected by anti-HEV ELISA 
assay, fecal samples obtained from piglets were not tested for HEV RNA (3, 14) 
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Our findings demonstrated that there was no adverse effect of intravenous inoculation 
of pregnant gilts with U.S. swine HEV. Although the gilts shed swine HEV RNA in feces, 
there was no evidence of vertical transmission from dams to their fetuses. Pigs bom to swine 
HEV-infected dams acquired anti-HEV Immunoglobulin (Ig) G antibodies passively from 
colostrum and the passive antibodies persisted until the pigs were approximately 2 mo old. 
Based on our results, HEV-free pigs can be derived from HEV-infected dams by early 
weaning and segregation of the pigs from their dams. 
Fulminant hepatitis E was not reproduced in pregnant rhesus monkeys intravenously 
inoculated with 105 5 50% monkey infectious dose (13, 15). Similarly, fulminant hepatitis E 
was not reproduced in pregnant swine inoculated intravenously with swine HEV. In the 
current study, we used swine HEV inocula with a titer of 10 ^ PIDso. This inoculating dose 
has been repeatedly used and determined to be effective for inducing experimental HEV 
infection and mild hepatitis lesions in pigs (3,14). It is apparent that inducing experimental 
HEV infection via intravenous inoculation is more reproducible than via oral inoculation in 
non-human primates and swine (14,16). Perhaps, higher doses could result in clinical disease 
in the pregnant gilt model. 
The characteristics of hepatitis lesions observed in the inoculated gilts are consistent 
with those previously documented in growing pigs and are reportedly milder in pigs 
inoculated with swine HEV than in pigs inoculated with human HEV (3). With regard to the 
interstitial nephritis lesions found in 4 of 12 inoculated gilts, the lesions are unlikely related 
to swine HEV infection since there was no such lesion found in growing pigs inoculated with 
swine HEV (3). These nephritis lesions may be attributable to previous episodes of ascending 
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bacterial infection of the lower urinary tract. Recurrent lower urinary tract infections and 
nephritis in breeding aged pigs is common (17). 
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Table I. Reproductive parameters from swine hepatitis E virus (HEV) inoculated gilts versus 
control gilts. 
Parameter Inoculated gilts Control gilts 
Total fetuses or pigs per litter 11.8 12.5 
% Normal 73.9 76.0 
% Small or stillborn 7.7 12.0 
% Mummified fetuses NA NA 
<15 cm long (preinoculation) 17.6 9.3 
<15 cm long (postinoculation) 0.7 2.7 
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Table E. Anti-Hepatitis E virus (HEV) immunoglobulin (Ig) G antibodies enzyme linked 
immunosorbent assay (ELISA) in pigs bom from inoculated and control gilts. 
Number seropositive/Number tested (O.D. mean ± a)* 
Age (days) Inoculated gilts Control gilts 
10 13/16 (0.795 ± 0.502) 0/8 (0.000 ± 0.000) 
18 17/20 (0.880 ±0.501) 0/8 (0.069 ±0.013) 
32 14/22 (0.512 ±0.314) 0/8 (0.151 ±0.223) 
47 8/22 (0.261 ±0.153) 0/8 (0.043 ± 0.039) 
61 2/22 (0.176 ±0.090) 0/8 (0.071 ± 0.026) 
71 0/22 (0.138 ±0.052) 0/8 (0.066 ± 0.008) 
87 0/22 (0.121 ± 0.032) 0/8 (0.080 ± 0.008) 
102 0/22 (0.113 ±0.028) 0/8 (0.139 ±0.108) 
Pigs were weaned at 18 days of age. Pigs from control gilts were mixed with those from 
inoculated gilts at weaning. 
s - Standard deviation 
* ELISA O.D. cut-off value = 0.3 
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Table m. Presence of swine hepatitis E virus (HEV) RNA detected by nested RT-
polymerase chain reaction (RT-PCR) in samples from swine HEV-inoculated gilts and their 
fetuses. 
Number positive/number tested (DPI) 
Sample 0 6 12 26 
Gilts 
Serum 0/12 2/12 3/11" 0/6» 
Feces 0/12 12/12 12/12 0/8 
Liver NT NT 4/4 0/4 
Bile NT NT 2/4 0/4 
Fetuses 
Serum NT NT 0/8^ 0/8 
Pooled tissuesc NT NT 0/8 0/8 
DPI - Days post inoculation 
NT - Not tested, samples not tested on this DPI due to no necropsy 
a Serum samples of 1 or 2 inoculated gilts were not available at this DPI. 
^Number of litters (2 fetuses each) positive for swine HEV RNA/total litters tested 
^ Liver, lung, kidney, spleen, and small intestines 
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CHAPTER 5. 
ROUTES OF TRANSMISSION OF SWINE HEPATITIS E VIRUS IN PIGS 
A paper published in 
J b w r M o /  o f  C&'mca/42:5047-5052, 2004. 
Chaiyan Kasorndorkbua, Denis K. Guenette, Fang F. Huang, 
Pete J. Thomas, Xiang-Jin Meng, Patrick G. Halbur 
Abstract 
Hepatitis E virus (HEV) is believed to be transmitted by the fecal-oral route in pigs. 
To date, in experiments, HEV has been transmitted successfully by the intravenous or 
intrahepatic route. To assess the route of HEV transmission, 27 pigs were separated into nine 
groups of three pigs. Positive-control pigs were inoculated intravenously with swine HEV 
and served as the source of HEV for the other groups. Uninoculated contact pigs were placed 
in the positive-control group. On three consecutive days, naïve pigs were inoculated using 
samples collected from the positive-control pigs at 9,10, and 11 days postinoculation. The 
tonsils and nasal mucosa of each positive-control pig were swabbed and that swab was used 
to rub the tonsils, nasal and ocular mucosa of naïve pigs. The positive-control pigs were also 
injected with bacterid, and the same needle was used to immediately inject naive pigs. Feces 
were collected from positive controls and fed by oral gavage to naïve pigs. Weekly fecal and 
serum samples from each pig were tested for anti-HEV antibodies and HEV RNA. All 
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positive-control pigs shed the virus in feces; two were viremic and seroconverted to anti-
HEV. All contact control pigs shed the virus in feces, two seroconverted and one became 
viremic. One of three pigs in the fecal-oral exposure group shed the virus in feces and 
seroconverted. Pigs exposed to the contaminated needles or the tonsil/nasal secretions swabs 
remained negative. This is the first report of experimental fecal-oral transmission of HEV in 
swine. 
Introduction 
Hepatitis E virus (HEV) is an important cause of cnterically transmitted, non-A, non-
B hepatitis in humans. The virus is a non-enveloped, single-stranded, positive sense RNA 
virus (34). HEV has recently been classified as the prototype member in the Aepevirwa genus 
of the family Hepevirw&ze (9). The disease caused by HEV is typically characterized as a 
self-limiting acute hepatitis with low mortality (20). However, severe hepatitis has been 
reported in pregnant women with up to 25% mortality (20). 
HEV in humans is believed to be transmitted primarily by the fecal-oral route (21, 
34). HEV is endemic or epidemic in certain regions of the world including parts of Africa, 
Asia, and Mexico. Epidemics within endemic regions are usually associated with heavy rains 
or flooding in areas that lack proper drinking water sanitation (19). Individuals from non-
endemic regions who acquire HEV infection often have a history of traveling to developing 
countries where HEV is endemic (7, 14, 33). 
Recent sporadic human HEV infections in people who had not traveled to countries 
where HEV is endemic led to the discovery of novel HEV isolates in industrialized regions, 
such as the United States, Europe, Taiwan, and Japan. Sequence analyses revealed that these 
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HEV isolates are genetically divergent (11, 30, 31, 35, 36, 44, 48). The human and swine 
HEV isolates from industrialized countries are genetically clustered together in the same 
genotype (either genotype m or TV) raising concerns of hepatitis E as a zoonotic disease (3, 
10,15, 24,29,32, 35, 37,40, 45,47). Serological surveys of humans who are in close 
contact with pigs, such as swine veterinarians and pig handlers, showed an increased 
prevalence of anti-HEV antibodies in these occupational groups suggesting potential pig-to-
human transmissions (8, 27, 43). 
Pigs have been experimentally infected with a genotype m human HEV and swine 
HEV, and the HEV-infected pigs shed the viruses in feces for several weeks (13). Direct 
evidence of zoonotic HEV transmission has recently been reported in Japanese patients who 
acquired hepatitis after consumption of uncooked pig livers (22) or consumption of raw meat 
from wild deer (38). On the basis of the sequence available, the swine HEV isolate detected 
in a raw pig liver sold in a grocery store was genetically identical to a human HEV isolate 
recovered from one of the Japanese hepatitis E patients (47). 
The natural route(s) of swine HEV transmission in pigs remains unknown. Swine 
HEV can be transmitted experimentally via direct contact with infected pigs (25). Repeated 
direct daily contact among pigs reared in confinement buildings may enhance the spread of 
swine HEV. Pigs housed in the same pen are exposed to saliva, nasal secretions, urine, and 
feces of multiple pen mates repeatedly each day. Experimental transmission of HEV to naïve 
pigs via feces collected from swine HEV-infected pigs was achieved when inoculated 
intravenously, but not when the pigs were inoculated orally with an equivalent dose (17). 
Extrahepatic sites of HEV replication exist and include the intestinal tract (42). It is therefore 
logical to assume that, under natural conditions, swine HEV is transmitted via the fecal-oral 
route as is thought to be the case in human HEV infections (10,46). 
HEV viremia is transient and lasts only 1-2 weeks, whereas fecal virus shedding may 
persist for up to 7 weeks (13,25). Repeated use of needles for drug administration or 
vaccination is commonly practiced in swine health management. Even though HEV viremia 
is transient (1-2 weeks), it is possible that blood contamination of needles from viremic pigs 
may also be a means for HEV to spread among pigs on and between farms. The objective of 
the present study was to determine if swine HEV transmission occurs via exposure to (i) 
tonsil and nasal secretions from infected pigs (ii) repeated use of contaminated needles, and 
(iii) oral consumption of feces from infected pigs. 
Materials and Methods 
Virus inocula and pigs. The swine HEV inocula used in the present study was 
prepared from feces collected from pigs intravenously infected with the prototype strain of 
swine HEV (24). The inocula contained a HEV titer of 10^ 50% pig infectious dose per ml, 
which is equivalent to approximately 10^ genome equivalent (GE) per ml (26). The inocula 
were kept at -80° C until used. Twenty-seven, 3-week-old, specific-pathogen-free pigs (&w 
aero/% were used in this study. All pigs were confirmed to be free of swine HEV 
in feces by nested RT-PCR prior to inoculation (26). 
Experimental design. The experimental design consisted of one negative control, 
three sham-inoculated, and five exposure groups (Table 3). Each group contained three pigs 
and was housed separately. In the exposure groups (groups 3,4, and 5), each pig was in a 
different, individual pen to avoid direct contact with body secretions or excretions from other 
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pigs in the same groups. Three pigs were intravenously inoculated with the swine HEV 
inocula and served as positive controls and virus shedders (group 1). Three pigs were non-
inoculated and served as negative controls (group 6) and as the source for swine HEV-
negative inocula used in the three sham exposure groups. Three uninoculated pigs were 
housed in the same pen containing the three-positive control pigs to serve as direct-contact 
controls (group 2). The three exposure routes chosen in the study were designed to evaluate 
three potential transmission routes likely to occur under current swine production practices: 
(i) tonsil and nasal secretions, (ii) repeated use of needles, (iii) fecal-oral route. 
In the tonsil and nasal secretions exposure group (group 3), sterile plastic Dacron 
swab applicators (Medical Packaging Corp., Camarillo, Calif.) were used to collect tonsil and 
nasal secretions from each of the three pigs (a separate swab for each pig) in the positive-
control group (virus shedders) by repeatedly and aggressively rubbing the palatine tonsil 
surface and the nasal mucosal surfaces, respectively. Each of the contaminated swabs was 
then placed in a separate sterile plastic container and applied to one of the naive pigs in the 
exposure group by rubbing the palatine tonsil surface, nasal mucosal surfaces, and palpebral 
and bulbar conjunctiva, respectively. 
In the needle exposure group (group 4), a l-in.-long, 18-gauge, hypodermic needle 
and a 3-ml syringe were used to vaccinate three positive control pigs intramuscularly in the 
neck with 2 ml of Afycqp&ZMMa Aj/opmew/Momae bacterin (Respisure, Pfizer). The needle was 
then removed and placed in a sterile plastic bag to repeat the administration of the vaccine to 
three naive pigs in the needle exposure group. 
In the fecal-oral exposure group (group 5), 15 g of fresh feces collected from each of 
the shedder pigs was pooled and mixed, and then 15 g of pooled feces was administered by 
oral gavage to each of the three naive pigs in the fecal-oral exposure group. The pigs were 
monitored for 5 minutes to assure that no regurgitation occurred after the gavage. 
The three inoculation procedures were repeated for three consecutive days (9 to 11 
days post inoculation [dpi] of the positive-control shedder group). Three sham-inoculated 
controls (group 7, 8, and 9) were inoculated in similar manners to the corresponding 
exposure groups, except that the sham inocula were obtained from three swine HEV-free 
negative-control pigs (group 6). To prevent potential cross contamination via people moving 
from the shedder group into exposure groups, two separate teams were involved in the 
collection of exposure inocula and inoculation. 
The serum samples and fecal swabs from the positive control shedders were collected 
daily from 3 to 14 dpi and stored at -80° C for the detection of HEV RNA by qualitative and 
quantitative RT-PCR. The tonsil and nasal swabs, serum samples, and fiscal swabs collected 
on 9, 10, and 11 dpi were tested for HEV RNA by RT-PCR, and the positive samples were 
further tested by quantitative real-time RT-PCR. Fecal swab and blood samples were 
collected weekly from all pigs until the end of the study at 56 dpi. All fecal and serum 
samples were stored at -80° C until tested. 
Detection of swine HEV RNA by nested RT-PCR. RNA extraction was performed 
by the modified spin column method (QIAamp; QIAgen, Chatsworth, Calif.) as previously 
described (2). Portions (140 p.1) of fecal suspension or serum samples were used for RNA 
extraction. The RNA extract was then immediately used for the reverse transcription reaction 
and cDNA synthesis in a reaction containing 11.5 ^1 of RNA, R1 reverse primer, and 
Superscript H reverse transcriptase (GIBCO-BRL) at 42° C for 1 hour. A nested RT-PCR 
assay specific for the prototype United States strain of swine HEV was performed as 
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previously described (17). The first-round PCR primers were the forward primer F1 (5'-
AGCTCCTGTACCTGATGTTGACTC-3') and the reverse primer R1 (5'-
GCTACAGAGCGCCAGCCTTGATTGC-3') and yielded a PCR product of 404 bp. The 
second-round PCR primers included the forward primer F2 (5'-
GCTCACGTCATCTGTCGCTGCTGG-3') and the reverse primer R2 (5'-
GGGCTGAACCAAAATCCTGACATC-3') and produced a PCR product size of 266 bp. 
Ten microliters of cDNA was used as the template for the first round of PCR in a 100-jil 
PCR mixture. The first-round of PCR was initiated with the activation of ampliThg Gold 
DNA polymerase at 95° C for 9 min. There were 39 cycles in the first round of PCR, with 1 
cycle consisting of denaturation (1 min at 94° C), annealing (1 min at 52 ° C), and extension 
(1.5 min at 72 ° C). The first round of PCR concluded with a final incubation step (7 min at 
72 ° C). Similar PCR parameters were used for the second round of PCR. The amplified PCR 
products were examined by 1% agarose gel electrophoresis. The PCR products were directly 
sequenced to confirm that they are indeed swine HEV sequences. 
Detection of Immunoglobulin G anti-HEV antibodies by ELISA. Serum samples 
were tested by an enzyme-linked immunosorbent assay (ELISA) using a purified 55-kDa 
truncated recombinant capsid protein of human HEV strain Sar-55 as previously described 
(24,26). Each serum sample was tested twice. The final optical density values were averages 
of the two results. Preimmune and hyperimmune swine sera were used as negative and 
positive controls, respectively. 
Quantitative real-time RT-PCR. Representative samples of feces, tonsil and nasal 
secretions, and serum were collected daily from three shedder pigs in the positive-control 
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group for three consecutive days during the period of exposure inoculation (9,10, and 11 
dpi). Swabs of pooled fresh feces (used as inocula) were resuspended in 1-ml portions of 
sterile phosphate buffer saline (PBS). Swabs of tonsil and nasal secretions were resuspended 
in 1-ml portions of sterile PBS. 
All representative samples were subjected to a quantitative real-time RT-PCR assay. 
A standard curve for the quantification of swine HEV genome was generated using an in 
vitro swine HEV ORF2 cDNA plasmid as previously described (42). In vitro-transcribed 
RNA was quantitatively measured by a spectrophotometer. Serial 10-fbld dilutions from 100 
ng to 10 fg were made and subjected to quantitative PCR. All representative samples of three 
exposure inocula on 9,10, and 11 dpi were tested in triplicate using the iCycler system (Bio-
Rad). SYBR Green 1 was used to detect PCR product. The amount of viral RNA in the 
samples was derived from the standard curve using the mean of the cycle threshold values 
generated. For the amount of viral RNA in a given sample, viral genome copy numbers were 
calculated according to an equation published elsewhere (5). 
Results 
The three positive-control pigs inoculated intravenously with the swine HEV stock 
shed relatively large amounts of viruses in feces during the period (9 to 11 dpi) that the 
experimental transmission and exposure were performed (Pig A, B, and C in Tables 1 and 2). 
However, viremia was detected in only two of the pigs (pig B and C) at the times tested, and 
these pigs seroconverted to immunoglobulin G anti-HEV antibodies by the end of the study 
(Table 1). Two of the three positive-control pigs exhibited fecal virus shedding during the 
entire exposure period (on 9 to 11 dpi) (Table 2). Pig A shed virus in feces on 4, 7, 8, and 10 
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to 14 dpi, pig B shed virus in feces on 4 and 7 to 14 dpi, and pig C shed virus in feces on 3 to 
5 and 7 to 14 dpi. Only pig B had three consecutive days of viremia during the exposure 
period from 9 to 11 dpi (Table 2). Viremia was detected in pig B on 5, 6, and 8 to 14 dpi 
(Table 1). The HEV genomic titers in serum samples obtained from pig B were 2.8 X 10*, 
4.4 X 10*, and 6.6 X 10* copies per ml of sera on 9,10, and 11 dpi, respectively (Table 2). 
Viremia was not detected in pig A or pig C during the exposure period (9 to 11 dpi) or at any 
time prior to 14 dpi (3 to 13 dpi daily). Pig A was not viremic at any time tested from 14 to 
56 dpi; however, viremia was detected in pig C on 14 and 21 dpi (Table 1). 
The results of quantitative real-time RT-PCR for HEV genome during the period of 
exposure are summarized in Table 2. The HEV genomic titers in fecal samples from pig A 
were 2.7 X 10* and 10.5 X 10* copies per g of feces on 10 and 11 dpi, respectively (fecal 
sample from this pig was negative for HEV RNA by RT-PCR on 9 dpi). The genomic titers 
in fecal samples of pig B were 2.9 X 10*, 3.7 X 10*, and 10.5 X 10* copies per g of feces on 
9, 10, and 11 dpi, respectively. Pig C had 3.8 X 10*, 6.2 X 10*, and 13.2 X 10* copies per g 
of feces on 9,10, and 11 dpi, respectively. The tonsil and nasal secretion swabs collected 
from the shedder pigs (A, B, and C) were negative for HEV RNA during the period of 
exposure inoculation (9 to 11 dpi). 
Although all three contact control pigs shed the virus in feces, only two of these pigs 
seroconverted by the end of the study on 56 dpi (Table 3). One of the two seropositive pigs 
was also viremic on 21 dpi. Only one of three pigs in the fecal-oral exposure group shed the 
virus in feces (from 21 to 35 dpi) and seroconverted by 56 dpi. Viremia was not detected in 
that pig on the days tested (14, 21, 28, 35,42, 49, and 56 dpi). Pigs in the other exposure and 
sham inoculation groups remained negative for swine HEV RNA and anti-HEV antibodies 
throughout the study. 
Discussion 
This is the first report of successful transmission of HEV in pigs by the fecal-oral 
route. Of the three possible routes of HEV transmission (tonsil and nasal secretions, 
contaminated needles, and fecal-oral exposure) investigated under the conditions of this 
study, the fecal-oral route was the only route of exposure through which HEV transmission 
was achieved. However, it remains unclear if the fecal-oral route of exposure accounts for the 
high incidence of HEV infection in the global pig population, since we achieved transmission 
in only one of three pigs by the fecal-oral route. 
In contrast to the contact control pigs, and to the way pigs are typically raised in the 
field, the three pigs in the fecal-oral exposure group were placed in individual pens in the 
same room to decrease the likelihood of exposure to feces and urine from other pigs in the 
room. Aerosol transmission would not have been prevented by the room and pen design. 
Since transmission did not occur from pig to pig within the room, aerosol transmission is not 
likely. The flooring of the animal pens used in the study was raised, plastic-coated metal wire 
decks which accumulate minimal amounts of feces. In contrast, under Geld conditions, most 
pigs are raised in confinement facilities that have 25 to 200 pigs per pen and a combination 
of solid and slatted concrete flooring, which generally allows for more feces to accumulate 
and thus for repeated exposure to feces from multiple pigs. 
Experimental HEV infection by oral inoculation in nonhuman primates has reportedly 
been less reproducible than intravenous inoculation (1). Furthermore, an attempt to reproduce 
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swine HEV infection by oral inoculation in pigs was unsuccessful with a single dose of a 
standard swine HEV stock that was infectious when given intravenously (17). This suggests 
that swine HEV infection in pigs requires either a higher titer or repeated exposure to initiate 
infection via the fecal-oral route. Direct and repeated contact among large numbers of pigs 
within the same pen would increase the likelihood of repeated exposure to pigs excreting a 
high dose of HEV in feces. It is obvious that the infectious dose of HEV required for 
successful HEV transmission is different for the intravenous and oral routes of exposure. It 
has been demonstrated that a HEV titer of 1CP GE was sufficient to induce HEV infection in 
pigs when the virus was inoculated intravenously on a single day (17); however a higher titer 
of more than 10* GE and repeated exposure (for 3 consecutive days) was essential for 
transmission via the fecal-oral route, and this was successful in only one of three pigs in the 
present study. 
Others have reported that HEV infection in nonhuman primates is dose dependent 
(20, 39). All three shedder pigs in this present study shed what is considered a high titer of 
HEV (2.7 X 10* to 13.2 X 10* virus genomic copies per g of feces) in their feces, particularly 
during the third day of the exposure inoculation (11 dpi). Feces from all three positive control 
pigs were pooled prior to inoculation. However, only one pig in the fecal-oral exposure group 
became infected. The reason for the discrepancy in HEV transmission among three pigs in 
the fecal-oral exposure group remains obscure. 
HEV is a temperature-sensitive, labile virus (4). The infectivity of HEV is reportedly 
diminished after a rapid change in temperature (4). In this study, the length of time between 
the collection of fresh feces from the rectum of HEV-infected pigs and the exposure 
inoculation was less than 5 minutes. The pooled fresh feces collected were at ambient 
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temperature until subsequently given orally to naïve pigs. Inactivation of the virus in such a 
short period under these conditions should be minimal. 
In contrast to the fresh feces used in this experiment, a suspension (10% [wt/vol] in 
PBS) of feces was used as inocula in our previous study in which we failed to transmit HEV 
by the fecal-oral route (17). In that study, the fecal suspensions were clarified by 
centrifiigation at 1,100 X g for 10 min, and the supernatant was stored frozen at -80° C for up 
to 4 years (17). The same frozen fecal suspension was used as the intravenous inocula for the 
"shedder" pigs in the current and previous experiments (13,17,18). The freeze-thaw process 
might have affected the ratio of infectious to defective HEV particles (4, 23) and contributed 
to the unsuccessful transmission of the HEV via the oral route in a previous experiment (17). 
Proteolytic degradation of the infectious HEV particles in the intestinal tract of the 
host may also inactivate infectious HEV particles (4). However, inactivation of the HEV 
particles within the intestinal tract may be offset by newly assembled HEV virions 
originating from in azfw replication in the intestines, thus maintaining a high amount of the 
infectious virus particles in the feces (42). HEV infection in the intestinal mucosa without a 
systemic HEV infection may explain why one positive-control pig and some contact control 
pigs shed HEV in feces but did not develop HEV viremia (one of three pigs) or anti-HEV 
antibodies (two of three pigs). The lack of systemic HEV infection may explain the inability 
to detect HEV viremia and the insufficient serum antibody response in some pigs. 
HEV RNA was not detected in the tonsil and nasal cavity secretions tested in this 
experiment during the period of viremia. There is no evidence that tonsils and salivary glands 
support replication of swine HEV (42), so it is not surprising that the pigs in the tonsil and 
nasal exposure group failed to become infected. This is further supported by the lack of 
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evidence of transmission to noncontact pigs breathing the same air as the pigs in the fecal-
oral exposure group. It is unlikely that the nasal mucosa or respiratory tracts are the portals of 
viral shedding or routes ofHEV infection. Urine is also less likely to be a source of HEV 
transmission in pigs, since there is no evidence that swine HEV replicates in kidney (42). 
Repeated use of the same needle and syringe is common when vaccines and drugs are 
administered to growing pigs on commercial pig farms. We chose to use a A/ycop&isTMa 
/ryopMewmomae vaccine since this type of vaccine is commonly administered to pigs between 
5 to 12 weeks of age, when HEV transmission likely occurs (24). The volume of residual 
blood in used needles varies depending on the route of injection, the size of the hypodermic 
needle, and the volume and type of syringe. Up to 7.5 pil of residual blood was transferred 
during sharing of needles by intravenous drug users. In needle sharing simulations, the blood 
volume was increased when a 2-ml syringe was used than when a 1-ml syringe was used 
(12). In the present study, we used an 18-gauge and 1-in.-long needle on a 3-ml syringe for 
three consecutive days of the exposure inoculation process. Much larger multiple-dose 
syringes (i.e., 50 ml and larger) are typically used in the swine industry. The doses were 
administered into muscle in the present study, so residual blood in the needle would be less 
than that of the needles used for intravenous injection. Furthermore, there is no evidence that 
skeletal muscle is the site of replication for HEV (42) or that pork meat contains a detectable 
amount ofHEV (17). 
The HEV viremic period is variable and transient and generally lasts only about 1 to 2 
weeks (13,16,25). A recent survey of 99 pigs from several regions in Indonesia reported a 
sharp contrast between the prevalence of anti-HEV seroconversion (72%) and the number of 
pigs whose serum samples tested positive for HEV RNA (1%) (41). The transient and/or 
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intermittent characteristic ofHEV viremia may contribute in part to the ineffective 
transmission ofHEV through contaminated needles. From a comparative perspective, the 
injection of therapeutic drugs was not a risk factor for the high prevalence of anti-HEV 
antibodies in Danish patients who may have contracted HEV infection via the blood-bome 
route (6). Swine veterinarians in the United States who reported experiencing needle sticks or 
cuts with blood-to-blood contact were not at a significantly higher risk of anti-HEV 
seropositivity compared to those who had no history of such exposure (28). The inability to 
transmit HEV infection with used needle exposure in this experiment and the lack of 
epidemiological evidence of transmission of swine HEV to humans with exposure to pig 
blood may be due to an inadequate amount of infectious HEV particles in the blood on the 
contaminated needle or necropsy knives. 
In summary, the findings of the present study indicate that experimental fecal-oral 
transmission of swine HEV in pigs did occur but was not efficient. Efficient transmission of 
swine HEV in pigs via the fecal-oral route may require repeated exposure and high doses. 
Evidence of the transmission of swine HEV through tonsil and nasal secretions was lacking. 
It also appears unlikely that the repeated use of needles represents a common means of swine 
HEV transmission in pigs. The ubiquitous nature of swine HEV in the swine population and 
the presence of swine HEV in pig feces for a considerably longer period than the length of 
HEV viremia also favors the fecal-oral route as the primary route of swine HEV 
transmission. However, it remains unknown if there are undetermined factors that may 
facilitate swine HEV transmission through the fecal-oral route to the degree that HEV 
infection is reportedly to be widespread in global pig populations. 
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Table 1. Viremia, fecal shedding, and seroconversion in positive-control (shedder) pigs 
inoculated intravenously with a swine HEV infectious stock 
Swine HEV parameter status" 
Swine HEV on the fallowing dpi: 
Pig parameter 
0 7 14 21 28 35 42 49 56 
A Fecal shedding + + + - - - - -
Viremia - - - - - - - -
Anti-HEV NT* NT NT - NT NT NT -
B Fecal shedding + + + + - - - -
Viremia b + - - - - - -
Anti-HEV NT NT NT - NT NT NT + 
C Fecal shedding + + + - - - - -
Viremia - + + - - - - -
Anti-HEV NT NT NT + NT NT NT + 
° -, negative; +, positive; NT, not tested. 
* Pig B was negative for HEV RNA at 7 DPI but positive on 5, 6, and 8 to 14 dpi. 
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Table 2. HEV genomic copy number in fecal and serum samples of positive-control pigs 
collected during the days when samples were taken from them for inoculation and exposure 
of naïve pigs 
HEV genomic copy no.° 
on the following dpi: 
Shedder pig Sample 9 10 11 
A Feces 2.7 10.5 
A Serum - - -
A Tonsil and nasal swab - - -
B Feces 2.9 3,7 10.5 
B Serum 2.8 4.4 6.6 
B Tonsil and nasal swab - - -
C Feces 3.8 6.2 13.2 
c Serum - - -
c Tonsil and nasal swab - - -
° The number of virus genomic copies X 10 per gram of feces or per milliliter of serum is 
shown for the feces and serum samples, respectively. 
* The sample was negative for HEV RNA by RT-PCR, so quantitative PCR was not done. 
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Table 3. Detection of anti-HEV serum antibodies by ELIS A and ofHEV RNA by RT-PCR in 
pigs inoculated with biological samples from HEV-infected pigs 
Group Inoculation Route No. of positive pigs = 3/ 
Seroconversion HEV RNA 
in feces 
HEV RNA 
in serum 
1 Swine HEV positive control'' 2/3 3/3 2/3 
2 Direct contact exposure to positive 2/3 3/3 1/3 
control 
3 Tonsil and nasal secretions exposure 0/3 0/3 0/3 
4 Needle exposure 0/3 0/3 0/3 
5 Fecal-oral exposure 1/3 1/3 0/3 
6 Negative control 0/3 0/3 0/3 
7 Sham tonsil and nasal secretions 0/3 0/3 0/3 
exposure 
8 Sham needle exposure 0/3 0/3 0/3 
9 Sham fecal-oral exposure 0/3 0/3 0/3 
° Number of positive pigs of three pigs tested on 56 dpi. 
* Inoculated intravenously with swine HEV. 
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CHAPTER 6. 
HEPATITIS E VIRUS IN PIG MANURE STORAGE FACILITIES 
IS INFECTIOUS TO PIGS BUT EVIDENCE OF GROUND WATER 
CONTAMINATION IS LACKING 
A paper submitted to 
aW TTMviron/MgMfaZ MzcroNoZogy 
Chaiyan Kasomdorkbua, Fang F. Huang, Denis K. Guenette, 
Pete J. Thomas, Xiang-Jin Meng, Patrick G. Halbur 
Abstract 
Fresh feces, manure (from earthen lagoons and/or concrete pits), and drinking and 
surface water samples were collected in the summer and autumn of 2002 from 28 pig farms 
in the Midwestern United States. All samples were tested for swine HEV RNA by RT-PCR 
assay. Seven of 28 farms had fresh fecal samples that contained HEV RNA. In pit samples, 
15 of 28 farms contained HEV RNA. Of 8 farms that had lagoons, 3 contained HEV RNA. 
The highest virus titers were 10 and 10^ genome equivalent per 60 ml of manure in lagoon 
(designated as lagoon A) and pit (designated as pit B) samples, respectively. None of the 
water samples were positive for HEV RNA. To determine the infectivity of the HEV found 
in the positive lagoon or pit samples, pigs were inoculated either intravenously (n=3) or 
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orally (n=3) with the lagoon A or pit B manure. Four pigs inoculated intravenously with 
swine HEV served as positive controls. Three pigs served as uninoculated controls. All 
positive control pigs became infected and shed the virus in feces, and 3 of 4 developed anti-
HEV antibodies. Two pigs in the intravenously-inoculated pit B group shed the virus in feces 
and one of the pigs seroconverted to anti-HEV antibodies. None of the pigs in the negative 
control, the lagoon A oral, the lagoon A intravenous, or the pit B oral group shed the virus in 
feces. The findings indicate that HEV found in pig manure was infectious to pigs when 
inoculated intravenously. Pit manure is a potential source of infection of pigs and for 
contamination of the environment with swine HEV. However, contamination of drinking or 
surface water with HEV was not found on or nearby the pig farms. 
Introduction 
Hepatitis E virus (HEV) is the etiologic agent of an acute self-limiting non-A, non-B 
hepatitis in humans (46). The virus is a non-enveloped positive-sense single-stranded RNA 
virus and is recently given taxonomic status in the genus of Hgpewrw?, a member of the 
family (10). Human infection with HEV typically manifests as acute icteric 
hepatitis. However, chronic hepatitis associated with HEV has not been reported (11, 28, 46). 
The overall mortality is low, except for pregnant women that may suffer severe and fatal 
hepatitis with mortality rates up to 25% (28, 29, 30). HEV infection is distributed worldwide 
and is endemic in parts of Africa and Asia (28, 50). 
Human HEV outbreaks in endemic regions are reportedly associated with flooding 
and heavy rains through the fecal-oral route of transmission (8,11). HEV infection in non-
endemic industrialized countries is sporadic and is often reported in human patients with a 
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history of traveling to endemic countries; however, increasing reports of sporadic human 
HEV infection in non-endemic countries such as Japan, Greece, Italy, and the United States 
(U.S.) in patients without a history of traveling to endemic regions have been reported 
recently. The human HEV discovered in non-endemic, industrialized countries appears to be 
closely related to the swine HEV found in the same countries (5, 11, 43, 45, 47,48, 61). 
Pigs are a natural host for HEV (22, 35, 38, 61). HEV infection is globally ubiquitous 
in the pig population (6, 13, 19, 22, 38, 40, 41, 42, 47, 50, 51, 54, 55, 59, 60, 63). The fecal-
oral route is thought to be the primary mode ofHEV transmission (11, 60). Pigs infected 
with HEV shed the virus in feces in large amounts for 3-4 weeks whereas viremia is transient 
and persists for 1 to 2 weeks (15, 25, 26). A study ofHEV infection incidence in pig farms 
suggested that swine HEV is likely transmitted via the fecal-oral route (60). Current pig 
raising practice allow repeated exposure of pigs to feces and thus potentially to high doses of 
HEV (26, 60). 
Evidence of animal-to-human transmission ofHEV has recently been documented in 
a case where ingestion of uncooked liver obtained from a wild boar may have transmitted the 
infection (32). Consumption of uncooked meat collected from wild deer has caused human 
hepatitis E infection in 2 Japanese families (52). Livers collected from pigs experimentally 
inoculated with swine HEV contained viable HEV and the virus in the livers was infectious 
to pigs when inoculated intravenously (26). 
Human and animal raw sewage has been reported to contain HEV and the virus found 
in the human sewage was infectious as confirmed by a bioassay in non-human primates 
inoculated intravenously (43,44). Pig-to-human transmission ofHEV has been suggested by 
serological surveys (9, 34, 35, 58). It has been shown experimentally that a U.S. human HEV 
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strain infects pigs and swine HEV infects non-human primates (15, 37). Food-bome or blood 
transfusion routes have been implicated as likely means of origin of sporadic cases of human 
HEV infection in non-endemic industrialized countries (31, 32, 52, 62). Contamination of 
drinking or surface water in the vicinity of pig production facilities is possible and of concern 
(50). The status ofHEV in pig manure in storage facilities such as concrete pits and earthen 
lagoons remains to be investigated. If HEV is indeed present in stored pig manure it needs to 
be determined if the virus is infectious to pigs or other animals. The objectives of the present 
study were; (i) to determine whether HEV is present in pig feces and stored manure, on-site 
drinking water supplies, and surface water near swine production facilities, and (ii) to 
determine if HEV found in pig manure and/or water samples is infectious to naïve pigs. 
Materials and Methods 
Fecal sample collection and processing. In the late summer and autumn of2002,28 
pig farms located in the Midwestern United States (Iowa) were visited and sampled. Fresh 
feces from 5 live pigs per farm were collected, pooled, and prepared as 10% (wt/vol) fecal 
suspension in DEPC water-based phosphate-buffered saline (PBS). 
Manure sample collection and processing. Samples of manure in pits and lagoons 
were randomly obtained from 10 different sites of each manure storage facility and collected 
in a 50 ml sterile centrifuge tube. Ten manure samples were collected from the concrete pit 
under the slats of each finishing facility. The samples were taken from 10 randomly selected 
sites in each pit. Each sample was collected from a depth between one and two feet below the 
surface and directly below the pig pens. For the lagoon manure samples, 10 samples were 
randomly collected at a depth of 4 to 6 feet under the surface crust. 
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All samples were transported on ice to the laboratory. The ten tubes of each manure 
sample from each storage facility (pit and/or lagoon) were pooled together in two aliquots of 
250 ml. All fecal suspensions and manure samples were kept at -80° C until tested by RT-
PCR assay. Portions (60 ml) of the manure samples were subjected to ultracentrifuge 
protocols to concentrate virus particles (44). The manure samples were clarified at 1,100 x g 
for 10 min at 4° C. The supernatant was ultra-centrifuged at 229,600 x g for 1 h at 4° C to 
pellet the virus particles. The virus pellet was then diluted with 10 ml of 0.25 M glycine 
buffer (pH 9.4) on ice for 30 min. The dissolved virus pellet was re-centrifuged at 12,000 x g 
for 15 min at 4° C to discard solid materials. The supernatant of the virus pellet was saved 
and ultra-centrifuged at 229,600 x g for 1 h at 4° C to produce a final virus concentrate. The 
final virus concentrate was resuspended with 400 pi of DEPC water-based PBS. Two 
aliquots of 200 p,l each were prepared for qualitative nested RT-PCR and for semi­
quantitative nested RT-PCR which were kept at -80° C until tested. The manure concentrate 
samples that were positive for HEV RNA by the qualitative RT-PCR were further titered for 
HEV by the semi-quantitative RT-PCR. 
Water sample collection and processing. On each farm visited, 10 liters of on-site 
drinking water and 10 liters of water from the nearest upstream and downstream surface 
water (creeks, streams, or rivers) within a 0.25 to 6 mile radius of the pig farms were 
collected and concentrated. All water samples were collected in a sterile 10-liter container. 
Drinking water samples were directly obtained from a hydrant or faucet in or near the pig 
bams. Surface water samples were directly collected from the water source by submerging 
the container below the water surface. The water samples were transported in a cooler with 
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ice packs to the laboratory and were processed for virus concentration upon arrival within a 
day of collection. 
The concentration protocols were modified from Abbaszadegan et al., 1999 (1) and 
the guidelines for detection of enteric viruses recommended by U.S. Environmental 
Protection Agency, 1995 (4). Ten liters of water samples were run through a sterile unit of a 
filter housing (CUNO, Inc., Maiden, CT.) and cartridge (Virosorb® MDS1, CUNO, Inc., 
Meriden, CT ). All flow-through water was discarded. Once the filtering process was 
complete, 1 liter of autoclaved 0.25 M glycine buffer (pH 9.4) was used to elute the 
entrapped virus particles in the filter cartridge. The elution process was performed twice by 
using the first viral eluate for the second elution process. The virus eluate was immediately 
neutralized at pH 7-7.4 with 1 N HCL (pH 1.5), mixed vigorously, and kept on ice before 
proceeding to the virus concentration process by organic flocculation (4). The neutralized 
virus eluate was adjusted to lower its pH to 3.5 with 1 N HCL and 12 g of autoclaved beef 
extract powder and stirred vigorously for 15 min. The pH-adjusted virus eluate was then 
centrifuged at 3,000 x g for 10 min at 4° C. The supernatant of the virus eluate was discarded 
and the resulting pellet was re-suspended with 50 ml ofDEPC water-based PBS. The 
suspended virus pellet was made into 2 aliquots of 25 ml. One aliquot was subjected to the 
centrifugal concentration process to adjust the eluate volume for qualitative RT-PCR testing 
and the other was kept at -80° C for an archival purpose. The virus eluate for RT-PCR was 
subjected to 1,100 x g for 20 min in a Centrifugal Filter unit (Centricon®, Millipore 
Corporation, Billerica, MA.) to concentrate the eluate volume for the RNA extraction steps. 
To determine the sensitivity of the water concentration used in the present study, 10 
liters of tap water was spiked with one ml of a swine HEV infectious fecal pool (10% wt/vol) 
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with a titer of 10^ genome equivalent (GE) per ml (37). The swine HEV-spiked water was 
processed through the protocols described above and the spiked virus eluate was tested by 
swine HEV-speciGc RT-PCR assay and found to be positive for swine HEV RNA. 
Universal nested RT-PCR. Hepatitis E virus is heterogenic in the United States 
swine populations (22). A nested RT-PCR assay designed to detect genetically-variable 
strains ofHEV was used to amplify HEV nucleic acid (22). This universal RT-PCR was used 
to test the concentrated manure (collected either from concrete pit or earthen lagoon 
facilities) and concentrated water samples (collected either from surface water sources or on-
site drinking water). The modified spin column method (QIAamp; Qiagen, Chatsworth, CA.) 
was used to extract total RNA from 140 pi of concentrated manure and water samples or 
fecal suspensions (3). The RNA extract (11.5 pi) was then immediately used for the reverse 
transcription reaction for HEV cDNA synthesis. The first round PCR primers comprised the 
forward primer F1 [5'-AATTATGCC(T)CAGTAC(T)CGG(A)GTTG-3'] and the reverse 
primer R1 [5'-CCCTTA(G)TCC(T)TGCTGA(C)GCATTCTC-3']. The second round primers 
were the second forward primer F2 [5'-GTT(A)ATGCTT(C)TGCATA(T)CATGGCT-3'] and 
the second reverse primer R2 [5'-AGCCGACGAAATCAATTCTGTC-3']. The second-
round amplified PCR product of 348 base pairs (bp) in length was visualized by gel 
electrophoresis. For the PCR parameters used in the universal RT-PCR reactions, we strictly 
followed the protocol published by Huang et al., 2002 (22). To avoid false positive results 
from contamination during PCR reactions, positive (a standard infectious fecal pool 
containing swine HEV) and negative controls (sterile PBS) were added in every set of PCR 
reactions. 
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Semi-quantitative nested RT-PCR for titration of HEV in manure or water 
samples. To determine the virus titer in samples tested positive for HEV RNA, serial 10-fbld 
dilution in DEPC water-based PBS, ranging from 10"^ to 10"* dilution was made and 
subjected to the universal RT-PCR. The virus titer was reported as genome equivalent (GE) 
at the highest dilution found positive by the RT-PCR (36, 37). 
HEV genomic sequencing and phylogenetic analysis. PCR products amplified from 
pooled feces and manure were purified using the glass milk procedure with a GENECLEAN 
kit (Bio 101 Inc., Carlsbad, CA.) and then directly sequenced at the Virginia Tech DNA 
Sequencing Facility. Sequences of the PCR products were determined for both DNA strands. 
The primer sequences of the universal RT-PCR were excluded from the sequence and 
phylogenetic analysis. The resulting partial 225-bp sequences of positive feces and manure 
were analyzed and compared with the corresponding regions of prototype swine HEV and 
some known strains of swine HEV available in the GeneBank database by the MacVector 
computer program (Oxford Molecular Inc., Campbell, CA). Phylogenetic analysis was 
conducted with the aid of the PAUP program (David Swoffbrd, Smithsonian Institute, 
Washington, D C., distributed by Sinauer Associate Inc. Sunderland, MA.). A heuristic 
search with 1,000 replicates was used to produce a phylogenetic tree. The geographic origins 
and the GeneBank accession numbers of the nucleotide sequences of the HEV strains, 
representing four major genotypes (11) and including the recently-characterized avian HEV 
(16, 21), used in the phylogenetic and sequence analyses are as follows: human (h) HEV-Sar-
55 (Pakistan, M80851, genotype 1), hHEV-Mexican (Mexico, M74506, genotype 2), the 
prototype swine HEV (USA, AF082843, genotype 3) and hHEV-U.S.-2 (USA AF060669, 
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genotype 3), hHEV-Tl (China, AJ272108, genotype 4), and avian (a) HEV (USA, 
AY043166). 
Virus inocula. The swine HEV inocula used for inoculation of the positive control 
pigs was prepared from an infectious stock of feces collected from pigs intravenously 
infected with the prototype U.S. strain of swine HEV (38). The inocula contained a HEV titer 
of 10^ 50% pig infectious dose (PID50) per ml, approximately equivalent to 10^ GE per ml 
(37). The inocula were kept at -80° C until used. 
Swine bioassay. To determine if HEV RNA found in manure samples represented 
infectious virus particles, the HEV-positive pit and lagoon samples with the highest titer of 
HEV measured by semi-quantitative RT-PCR was prepared as inocula for naive pigs in a 
swine bioassay. Nineteen, 6-week-old, specific-pathogen-free pigs were randomly separated 
into 6 groups of 3-4 pigs. All pigs were anti-HEV seronegative by ELIS A and free ofHEV in 
feces by swine HEV-specific nested RT-PCR. Three pigs served as uninoculated controls. 
Four positive-control pigs were inoculated intravenously with the prototype U.S. swine strain 
(37). Four groups of three pigs each were inoculated with 25 ml of either a HEV-positive pit 
or lagoon sample via intravenous or oral route. The selected lagoon sample was collected 
from farm #19 and designated as lagoon A and the selected pit sample from farm #12 and 
designated as pit B. 
For preparation of the inocula, portions (150 ml) of the manure collected from lagoon 
A or pit B was dissolved in sterile DEPC water-based PBS to produce a manure suspension. 
The suspensions were clarified at 1,100 x g for 10 min at 4° C. Each pig was given 25 ml of 
the supernatant by intravenous inoculation (IV). The intravenous inoculation was performed 
for 5 consecutive days using 5 ml of the inocula per pig per day. The accumulative HEV titer 
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each pig received by intravenous inoculation was approximately 10 and 10^ GE for lagoon A 
and pit B, respectively. For oral inoculation, 25 ml of pooled pig manure from lagoon A or 
pit B was given to naïve pigs all at one time by oral gavage. The HEV titer each pig received 
for oral inoculation was approximately 10 and 10^ GE for lagoon A and pit B, respectively. 
Serum samples and fecal swabs were collected weekly for anti-HEV serum antibodies and 
detection ofHEV RNA. The bioassay was terminated on 56 days postinoculation (dpi). 
Detection of anti-HEV IgG antibodies by ELIS A. Serum samples were tested by an 
enzyme-linked immunosorbent assay (ELISA) using a purified 55-kDa truncated 
recombinant putative capsid protein of human HEV Sar-55 strain as the antigen (37, 38). 
Each serum sample was tested in duplicate, and mean optical density values above 0.3 were 
regarded as positive samples. Preimmune and hyperimmune sera were used as negative and 
positive controls, respectively. All pigs used in the swine bioassay were negative for anti-
HEV immunoglobulin (Ig) G antibodies prior to inoculation. 
Swine HEV-specific nested RT-PCR for fecal samples collected from the swine 
bioassay. Since the prototype U.S. swine HEV was used as the inocula for positive controls, 
a nested RT-PCR assay designed to specifically detect the prototype U.S. strain of swine 
HEV (15) was used to amplify HEV RNA in feces collected from the bioassay pigs in order 
to compare and differentiate between the HEV genomic sequence amplified from the 
prototype swine HEV (collected from the positive control pigs) and the genetically-variant 
HEVs potentially found in the lagoon or pit inocula (collected from pigs inoculated with the 
lagoon or pit inocula). The RNA extraction method and the volume of fecal suspensions used 
for this swine HEV-specific RT-PCR were similar to those performed for the universal RT-
PCR. However, the primers for the swine HEV-specific RT-PCR and PCR parameters were 
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different from those used for the universal RT-PCR as follows (15): the first round PCR 
primers comprised the forward primer F1 (5'-AGCTCCTGTACCTGATGTTGACTC-3') and 
the reverse primer R1 (5'-CTACAGAGCGCCAGCCTTGATTGC-3')_ The second-round 
PCR primers comprised the forward primer F2 (5-GCTCACGTCATCTGTCGCTGCTGG-
3') and the reverse primer R2 (5-GGGCTGAACCAAAATCCTGACATC-3') and produced 
an amplified PCR product size of 266 bp. To synthesize HEV cDNA portions (11.5 pi) of 
RNA extract was amplified in a reverse transcription reaction with R1 reverse primer and 
Superscript n reverse transcriptase (Invitrogen) at 42° C for 1 h. The cDNA (10 pi) was used 
as template in a 100-pl PCR reaction. The first-round PCR reaction was initiated with the 
activation of ampliTïay Gold DNA polymerase (Applied Biosystems) at 95° C for 9 min, 
followed by repeated 39 cycles of denaturation, annealing, and extension as follow; 94° C for 
1 min, 52 ° C for 1 min, and 72° C for 1.5 min, respectively, and finally, an incubation at 72° 
C for 7 min Similar PCR parameters were applied to the second round PCR reaction. The 
amplified PCR products were inspected on gel electrophoresis. 
Results 
Detection of HEV in feces, manure, and water. HEV RNA was detected in pooled 
fresh feces from 7 of the 28 farms. Fifteen of 28 farms were found to have HEV-positive 
manure samples collected from concrete storage pits. Three of 8 lagoons were positive for 
HEV RNA (Table 1). None of the concentrated water samples collected from on-site 
drinking water supplies or the nearest surface water sources (creeks, streams, or rivers) were 
positive for HEV RNA (data not shown). The highest virus titer in manure samples that 
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tested positive for HEV RNA was approximately 10 and 10^ GE in lagoon A and pit B, 
respectively (Table 1). 
Determination of the infectivity of HEV found in manure samples. The swine 
bioassay results are summarized in Table 2. All positive-control pigs shed HEV in feces from 
14 to 49 dpi and 3 of 4 positive control pigs developed anti-HEV antibodies by 56 dpi. 
Uninoculated control pigs remained HEV-free in feces and negative for anti-HEV IgG 
antibodies by the termination of the study on 56 dpi. Two pigs inoculated intravenously with 
the pit B inocula became infected with swine HEV. The presence of HEV RNA in fee es was 
detected in one pig in the pit B inoculated group by 14 dpi and in the other pig by 21 dpi. 
Both pigs continued to shed HEV in feces through 28 dpi. The pig that shed HEV in feces 
from 14 to 28 dpi seroconverted to HEV, whereas the other pig remained seronegative on 
termination of the study at 56 dpi. One of 3 pigs inoculated intravenously with manure from 
lagoon A seroconverted to anti-HEV antibodies by 56 dpi. 
Genetic variation of HEV isolates in pooled feces. Of 7 pooled fecal samples 
positive for HEV RNA, nucleotide sequence analyses of the amplicons revealed that the 7 
HEV isolates shared 88-94% identity with each other and 88-96% identity with the prototype 
U.S. swine HEV (Table 3). 
Genetic variation of HEV isolates in the pit or lagoon manure samples. A 
phylogenetic tree was built based on 225 bp-length sequences. Phylogenetic analysis 
indicates that HEVs amplified from manure samples collected from either pit or lagoon 
facilities are segregated within genotype 3 which is where the prototype swine HEV and the 
US-2 strain of human HEV are clustered (Figure 1). There were two farms (farm #18 and # 
19) where the HEVs found in pig feces and the pit or lagoon manure samples were more 
closely related to each other than to the HEVs from different farms. On one farm (F18 and 
PI 8), the HEVs from feces and pit manure were identical (Figure 1). 
Swine bioassay. The amplicon of HEV RNA from feces collected at 21 dpi from a 
pig (designated as pig I in Table 4) inoculated intravenously with pit B was 100 % identical 
to the amplicon of HEV RNA from the pit B intravenous inocula that the pig received. The 
amplicon of HEV RNA from feces collected on 21 dpi from the other pig (designated as pig 
II) in the pit B intravenous group was 93% identical to the pit B intravenous inocula that the 
pigs received (Table 4). 
Discussion 
Pig manure may be an appropriate sample, perhaps even better than fresh feces, to 
confirm the status of HEV infection of a population of pigs. More HEV positive sites were 
detected by testing manure samples from pits compared to testing fresh feces. The 
concentration protocols used in this study for detection of HEV in manure offer a reliable 
tool to detect small amounts of HEV RNA in large volumes of manure. The manure in the 
pits and lagoons likely represents HEVs from many pigs present at one time or another on 
that site over an extended period of time. 
In the present study, all manure samples were collected during late summer and 
autumn months of a year when the ambient temperature would be quite high compared to 
that in the winter months in the Midwestern U.S. The high temperature range at the time the 
manure samples were collected could have enhanced the biodégradation of organic waste in 
the manure storage facilities and decreased the amounts of HEV nucleic acids detectable by 
RT-PCR and the viability of the virus assayed. In contrast, low temperature during winter 
months may preserve the infectivity of environmental viruses for longer periods (39). 
The HEV isolates from the pooled feces and manure were genetically diverse but all 
clustered in the genotype 3 with the prototype U.S. swine HEV. Nucleotide sequence 
comparison showed that HEVs isolated from the pooled feces and pit and/or lagoon samples 
of the same farm are genetically more closely related to each other than those from different 
farms. 
Wild rats likely reside on pig farms. Therefore it is also possible that rats are an 
alternative source for contamination of pig manure storage facilities since a high prevalence 
of anti-HEV antibodies has been reported in wild rats (12,17,18,23). Demonstration of high 
affinity of partially amplified HEV genomes between wild rats and humans in Nepal suggests 
that wild rats may be a reservoir for HEV infection in humans and play a major role in HEV 
epidemics in such HEV-endemic countries (17). Interestingly, all HEVs found in the manure 
samples tested in the present study are phylogenetically clustered in the genotype 3, which is 
genetically distant from the rat HEV reported in Nepal, which was clustered in the genotype 
1 (17). 
HEVs are genetically heterogenic and both human and swine strains of HEV tend to 
be genetically clustered according to their geographical origins (6, 7,19, 22, 40, 43, 49, 51, 
54, 61). When genomic characterization of rat HEV becomes available a phylogenetic 
comparison with HEVs from humans, pigs and the manure samples in the current study will 
provide further insights into the likelihood that wild rats are a natural reservoir for HEV 
transmission to pigs and perhaps humans as has been suggested by serological studies (12, 
17,18,23). Wild deer may also gain access to manure in lagoons in the Midwestern U.S. 
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Since evidence of fbod-bome zoonotic transmission of HEV from deer to humans has been 
reported in Japan (52) it is tempting to speculate that wild deer may be another reservoir for 
HEV. To date, the status of anti-HEV antibodies in wild deer has not been reported in the 
U.S. It remains to be determined whether HEV exists in the U.S. wild deer populations and if 
deer may contribute to contamination of the environment with HEV and HEV transmission 
among humans, pigs, and other animals. 
The swine bioassay indicates that HEV found in pig manure was infectious to naive 
pigs when inoculated intravenously. Partial nucleotide sequences of the PCR amplicon 
amplified from the pit B inocula and 1 pig (pig I in Table 4) inoculated intravenously with 
the pit B inocula were identical, and were different from the amplicon amplified from the 
positive control pigs inoculated intravenously with the prototype swine HEV. This confirms 
that the virus found in the pit B inocula was infectious and replicated in pig I and was 
subsequently shed in the feces of that pig. The lack of complete nucleotide identity between 
the virus found in feces from pig II and the pit B inocula (and pig I) may reflect the genetic 
variability of different HEVs (HEV quasispecies) found in the manure since the amplicon 
from feces collected from pig II was different from that in the pit B manure or the prototype 
swine HEV. Evidence for quasispecies of HEV has recently been reported in an epidemic of 
human HEV infection (14). As an RNA virus, HEV may be prone to replication errors due to 
the function of the non-proofreading polymerase enzyme, leading to diverse populations 
(14). Another possibility that could have contributed to such a difference in the nucleotide 
identity includes random mutations during the PCR reaction (27). 
The swine bioassay findings are in accordance with a report of analysis in raw sewage 
drained from an urban area in Spain where HEV present in the biological waste facilities 
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remained infectious to experimentally-inoculated rhesus monkeys (44). Subsequently, the 
authors reported the presence of HEV in raw sewage drained from pig slaughterhouses. 
However, an animal bioassay was not performed to determine the infectivity of the HEV 
found in the raw pig sewage (43). HEV has recently been found in raw human sewage 
collected from industrialized countries including the U.S. According to the partial nucleotide 
sequence analysis, the HEV found in the human sewage was more homologous to the 
prototype U.S. swine HEV than to the US-1 and US-2 strains of human HEV (98.4% versus 
91.0%) (7). The prototype swine HEV is able to infect non-human primates (37). 
Although most individuals infected with swine HEV are likely subclinic ally infected 
(9, 34, 35), it is important to understand the source of such infections. Possibilities include 
consumption of pork products or consumption of water or food contaminated with pig feces. 
It is also possible that human sewage facilities are opened to wild rats or other animal 
reservoir species that shed HEV and that viruses detected in those facilities are not from 
humans. 
One pig each of the positive control and the pit B intravenously-inoculated (pig I) 
group remained HEV seronegative at the end of the study (Table 2.). It has been previously 
demonstrated that a few pigs experimentally-inoculated intravenously with swine HEV may 
have a delayed response to the infection and seroconversion to anti-HEV antibodies may 
occur beyond the 56 day duration of the experiment (26, 38). A recent study using an 
infectious clone of swine HEV in pigs showed that one pig inoculated intra-hepatically with a 
low virulent HEV clone did not develop detectable anti-HEV antibodies by 56 dpi (20). 
One pig inoculated intravenously with the lagoon A inocula seroconverted to HEV by 
56 dpi without detectable shedding of the virus in feces (Table 2). A possible explanation for 
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this discrepancy may be that the virus in the lagoon A intravenous inocula was able to induce 
an immune response in that particular pig (33); however, as the swine bioassay results 
indicate, the virus titer of 10 GE failed to induce HEV infection. Dose-dependent infectivity 
of HEV has been suggested in pigs (37) and nonhuman primates (53). It has been 
demonstrated that the effective titer to induce HEV infection, replication, and virus shedding 
in feces in pigs was 10^ GE when inoculated intravenously (26). An alternative explanation is 
that the pig did become infected and had brief localized replication of HEV in the intestines 
(57) and viremia and virus shedding in feces may have been intermittent and went undetected 
by weekly RT-PCR testing. 
Experimental studies of swine HEV transmission in pigs showed that fecal-oral 
transmission of HEV in pigs may occur, however it likely requires a higher dose and repeated 
exposure for successful transmission (24, 26). The results of this study are consistent with the 
previous findings that experimental oral inoculation is less efficient and requires a higher 
virus load in induction of HEV infection than intravenous inoculation since none of the three 
pigs inoculated orally with the pit B inocula became infected, whereas 2 of 3 pigs inoculated 
intravenously did (2,11, 26). 
HEV was not found in the ground or surface water samples tested with the 
concentration methods used in the present study. However, the methods used in the current 
study were able to detect HEV at a titer of 10^ GE when water was spiked with the prototype 
swine HEV. The dilution of the concentrated water samples with sterile PBS and the 
extraction protocols using the microspin column technique have been reported to minimize 
the inhibition of PCR reaction by potential inhibitors that have contaminated samples prior to 
the PCR reaction (3, 56). It is, therefore, possible that either the water samples tested in the 
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study lacked HEV particles or the level of contamination by HEV was below the detection 
ability of the concentration methods applied in the study. 
The RT-PCR used in the study has proven to be useful for the detection of swine 
HEV in animal organic waste reported here and raw sewage and biological samples reported 
elsewhere (7, 22,26, 43, 44). However, the RT-PCR assay does not differentiate between 
infectious and non-infectious virus particles since it is designed to amplify targeted nucleic 
acid of HEV genomes in the samples which may not reflect virus viability (1). Even though 
the bioassay is costly, until an effective cell culture system that supports in vitro HEV 
replication is developed, the swine bioassay may be essential to determine the infectivity of 
HEV found in the pig manure. It seems unlikely that consumption of water with levels of 
HEV below the level of detection with these methods would result in HEV infection in pigs. 
Cross species transmission of swine HEV to non-human primates has been 
demonstrated (37). Thus, it is prudent to assume that HEV present in pig manure waste could 
remain infectious and pose a risk as a source of transmission of HEV to humans. It is 
currently unknown how long HEV in pig manure waste can survive and remain infectious. 
More research on the survivability of HEV in different manure storage facilities and under 
different management practices of manure storage and application are warranted. 
In summary, HEV is present in pig farms and manure collected from concrete pits or 
earthen lagoons. Pig manure may be an appropriate sample, probably more suitable than 
fresh pig feces, to determine the presence of HEV on pig production sites. The swine 
bioassay findings indicate that HEV found in pig manure is infectious to naive pigs when 
inoculated intravenously. The presence of infectious HEV in manure storage facilities 
suggests that pit manure is a potential source of infection for pigs, other animal species, 
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humans, and for contamination of the environment with swine HEV. However, evidence of 
contamination of drinking water or surface water with HEV was not found on or nearby the 
pig farms with the detection methods used in the present study. 
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Table 1. Detection of HEV RNA in pooled pig feces and environmental samples collected 
from 28 pig farms. 
Farm ID Type of Farm Feces Pit 
(Virus titer") 
Lagoon 
(Virus titer) 
1 Farrow to finish b + (io") NA' 
2 Farrow - - -
3 Farrow to finish - - -
4 Farrow to finish - - NA 
5 Grow/finish - + (10) NA 
6 Grow/finish - NA -
7 Grow/finish - + (10) NA 
8 Grow/finish - - NA 
9 Grow/finish + + (10) NA 
10 Wean to finish - - + (10) 
11 Farrow to finish - + (10) 
+ (10^) 
NA 
12 Grow/finish + NA 
13 Farrow to finish - + (10) NA 
14 Grow/finish - + (10) 
+ (1(f) 
NA 
15 Grow/finish - NA 
16 Grow/finish - + (10) NA 
17 Farrow to finish - NA + (10) 
18 Wean to finish + + (10) NA 
19 Farrow to Gnish + NA + (10) 
20 Wean to finish - - NA 
21 Farrow to finish + + (10) NA 
22 Grow/finish + + (10) NA 
23 Farrow to finish - NA NA 
24 Grow/finish - NA NA 
25 Grow/finish + + (1(f) -
26 Grow/finish - + (10") NA 
27 Grow/finish - - NA 
28 Wean to finish - NA -
Total 7 of 28 15 of 22 3 of 8 
° The number of HEV genome titer as genome equivalent per 60 ml of manure sample, 
determined by semi-qualitative RT-PCR. 
* -, negative for HEV RNA by qualitative RT-PCR; +, positive for HEV RNA by qualitative 
RT-PCR, thus subjected to semi-quantitative PCR. 
' Sample not available at the farm. 
NA- Not available 
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Table 2. Swine bioassay results: detection of HEV RNA in feces and anti-HEV serum 
antibodies in pigs inoculated with manure samples. 
No. of positive pi; ;s on the following dpi; Anti-HEV 
Inocula Route 0 7 14 21 28 35 42 49 56 56 dpi 
Uninoculated - 0/3" 0/3 0/3 NT" NT NT NT NT 0/3 0/3 
Lagoon A Oral 0/3 0/3 0/3 0/3 0/3 0/3 NT NT 0/3 0/3 
Lagoon A IV 0/3 0/3 0/3 0/3 0/3 0/3 NT NT 0/3 1/3 
PitB Oral 0/3 0/3 0/3 0/3 0/3 0/3 0/3 NT 0/3 0/3 
PitB IV 0/3 0/3 1/3 2/3 2/3 0/3 0/3 NT 0/3 1/3 
Positive control IV 0/4 3/4 4/4 4/4 4/4 4/4 4/4 4/4 0/4 3/4 
3 Number of pigs positive/number of pigs tested 
b Not tested 
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Table 3. Pair-wise comparison of nucleotide sequence of the prototype swine HEV (sHEV) 
and HEV isolates identified from fresh pooled fecal samples collected from 7 pig farms. 
18" 12 19 9 21 25 22 
sHEV 92" 88 90 93 93 93 96 
18 91 92 92 94 94 92 
12 88 90 90 91 89 
19 94 92 91 90 
9 94 94 92 
21 94 93 
25 94 
22 
"Farm identification number. 
^Percentage of nucleotide identities in the ORF2 genes. 
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Table 4. Pair-wise comparison of nucleotide sequence of the prototype swine HEV (U.S. 
sHEV), the pit B inocula and HEV isolates identified from fecal samples collected at 21 dpi 
from pigs in the swine bioassay. 
U.S. sHEV Pigl PigH 
Pig I 92" 
Pign 91 93 
Pit B Inocula 92 100 93 
* Percentage of nucleotide identities in the ORF2 genes. 
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MHEVT1 
hUS2 
USsHEV 
Mexican 
aHEV 
5 changes 
Figure 1. A phylogenetic tree based on analysis of a 304-bp nucleotide sequence of the ORF2 
gene of HEV. Representative HEV strains of 4 major genotypes and a recently-classified 
avian HEV strain were included in the analysis. F, P, and L stands for the HEV sequence 
amplified from pooled fecal, pit, and lagoon sample, respectively, which are presented in 
Table 1. The number following the sample initial refers to farm identification in Table 1. A 
scale bar reflecting the numbers of character state changes is provided for the comparison of 
genetic distance. The sequence of fecal sample collected from farm # 25 was not available 
for analysis. 
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CHAPTER 7. 
INFECTION OF PIGS WITH AVIAN HEPATITIS E VIRUS 
A paper to be submitted to 
Vbw/Tza/ of CZmicaZ M/croAWogy 
Chaiyan Kasomdorkbua, Denis K. Guenette, Fang F. Huang, 
Pete J. Thomas, Xiang-Jin Meng, S. U. Emerson, R. H. Purceli, and Patrick G. Halbur 
Abstract 
Cross-species transmission of HEV from chickens to turkeys has been demonstrated; 
however, attempts to infect rhesus monkeys with avian HEV were unsuccessful. In the 
present study, we used a pig model to determine if HEV from chickens (avian HEV) or rats 
(rat HEV) was infectious to pigs. Thirty six, specific-pathogen-free pigs were randomly 
separated into 4 groups of 9 pigs each. Group 1 was inoculated with HEV-free fecal 
suspensions and served as the sham-inoculated group. Group 2 was inoculated with rat HEV. 
Group 3 was inoculated with avian HEV. In the rat and avian HEV groups, 6 pigs were 
inoculated with the corresponding virus and 3 pigs remained uninoculated and served as 
contact controls. Group 4 was inoculated with the prototype swine HEV. The inoculation 
route was intravenous for all groups. Necropsy of 3 pigs from each group was performed on 
7, 21, and 35 dpi. In the rat and avian HEV groups, 2 inoculated and 1 contact control pigs 
were necropsied at each time point. Liver and bile from sham-inoculated pigs were negative 
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for HEV RNA throughout the study. HEV RNA was not detected in feces from any pigs in 
the rat HEV group. Pigs inoculated with avian HEV shed HEV RNA in feces from 7 to 28 
dpi and were viremic from 7 to 21 dpi. HEV RNA was detected in liver and bile from 1 to 3 
pigs (including 1 contact control) in the avian HEV group. One contact control pig in the 
avian HEV group which was viremic on 7 dpi and shed HEV in feces developed anti-HEV 
antibodies on 35 dpi. Pigs in the swine HEV group shed HEV in feces from 7 to 28 dpi and 1 
pig was viremic on 21 dpi. HEV RNA was detected in liver and bile from 1 pig in the swine 
HEV group on 21 dpi. Two swine HEV-inoculated pigs seroconverted to HEV on 21 and 35 
dpi. Pigs in the sham- and rat HEV-inoculated groups remained seronegative throughout the 
study. Avian and swine HEV induced subclinical hepatitis; however, the lymphoplasmacytic 
hepatitis lesions were slightly more severe in the swine HEV group. The findings indicate 
that avian HEV is transmissible to pigs. This work may open new areas of study in the 
epidemiology of HEV. Pigs may be an excellent model for comparative molecular and 
pathogenetic studies of HEV. 
Introduction 
Hepatitis E virus (HEV) is the primary causative agent of acute, non-A, non-B 
hepatitis in humans (4). The infection is generally self limiting and typically has no chronic 
consequences (38). The mortality caused by HEV infection is reportedly low; however in 
pregnant women the mortality rate may be as high as 25%. Patterns of HEV transmission are 
different in developing and industrialized countries. In developing countries, epidemics of 
HEV infection are often associated with fecal contamination of drinking water following 
heavy rains or flooding (4, 38). In contrast, individuals in industrialized countries usually 
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contract hepatitis E while traveling to developing countries where HEV infection is endemic 
(30, 37). In recent years, the emergence of sporadic cases of human HEV infection has been 
reported in individuals residing in non-endemic countries and with no history of having 
traveled to endemic countries (3,22,27, 32, 41). Subclinical HEV infection may be more 
prevalent than previously thought particularly in industrialized countries (7,10). 
HEV is a non-enveloped, single-stranded, positive sense RNA virus (38). The virus 
has currently been designated as a in the family (9). HEV has been 
identified and characterized in pigs and chickens (13, 16,18, 35, 36). Swine HEV is 
genetically closely related to human HEV (17, 22, 27, 36, 40,45, 46). Pigs are thought to be 
a potentially important source of zoonotic infection of humans with HEV. 
Pigs are a natural host of HEV and swine HEV is globally ubiquitous in pig 
populations (3, 7, 10, 13, 22,25, 26, 34, 45, 46, 48); however, there is no clinical disease 
reported in pigs infected with HEV under natural or experimental conditions (15, 36). 
Natural transmission of HEV in pigs is thought to be via the fecal-oral route and this has 
been recently confirmed experimentally (29,48). Cross-species transmission studies have 
demonstrated that human HEV infects pigs and swine HEV infects non-human primates (15, 
35). Individuals who work in close contact with pigs (i.e. pig veterinarians, caretakers, and 
farmers) are more likely than the general population to have anti-HEV antibodies (8, 33, 34). 
Direct evidence of the zoonotic potential of swine HEV has recently been 
documented in a cluster of cases in which human HEV infection was reported in patients 
who consumed raw liver from a wild boar (32). HEV found in pig livers sold as food in 
grocery stores was found to be genetically highly homologous to a virus causing hepatitis E 
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m humans in Japan (49). Another recent human HEV infection was associated with the 
consumption of raw meat collected from two wild deer (44). 
Avian HEV was first discovered in bile samples of chickens with hepatitis-
splenomegaly (HS) syndrome in 2001 (18). Hepatitis-splenomegaly syndrome is a poorly-
described disease and the etiology remains unclear (39). The relationship between avian 
HEV and HS syndrome is not clear since antibodies against avian HEV were also found in 
healthy chicken flocks (25). Avian HEV is widespread in commercial chicken populations 
(43). The prevalence of anti-HEV in chickens increases with age and is similar to swine HEV 
infection in pigs (7, 36,43). Avian and swine HEV have certain similarities (24). Avian HEV 
is genetically and antigenically related to swine HEV (16). Analysis of nucleotide sequence 
revealed approximately 60% homology between the two viruses (25). Avian HEV recovered 
from chickens also has the ability to cross species barriers and infect turkeys; however, avian 
HEV was not transmissible to rhesus monkeys (24,42). 
Anti-HEV antibodies have reportedly been found in rodents from different 
geographical parts of the world (10,19, 28). Laboratory rats have been shown to be 
susceptible to experimental infection by a human HEV strain (31). It has been suggested that 
rats maybe an alternative reservoir of HEV (10). Evidence of rat-to-human transmission of 
HEV was suggested in Nepal where Hepatitis E is endemic (19). The genetic sequence of the 
rat HEV amplified in that study revealed similarity with genotype 1 HEV strains which 
predominantly occur in Asia (19). However, HEV in rats in the U.S. remains to be 
characterized (10). 
HEV is a recently discovered virus and the relatively large and diverse species prone 
to infection with HEV suggest that the virus may readily adapt to new hosts. Chickens, rats, 
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and pigs are commonly found together on farms across the world. The aim of the present 
study was to determine if HEV recovered from chickens or rats is infectious to pigs. 
Materials and Methods 
Virus inocula. The swine HEV inocula used in the present study was prepared from 
feces collected from pigs intravenously infected with the prototype strain of swine HEV (35). 
The inocula contained 10^ 50% pig infectious dose (PID#) of HEV per ml, which is 
equivalent to approximately 10* genome equivalent (GE) per ml (35). The avian HEV 
inocula used in the present study was prepared from bile and feces collected 6om chickens 
intravenously inoculated with avian HEV and contained a titer of 5 X 10^ 50% chicken 
infectious dose per ml (CID50) which is equivalent to approximately 10* GE (42). In a pilot 
study (C. Kasomdorkbua, unpublished data), 2 pigs did not become infected with avian HEV 
when intravenously inoculated with a HEV titer of 10* GE per ml (42) thus a higher titer was 
used in the current study. The rat HEV inocula originated from the liver of rats from Los 
Angeles, CA. in the U.S. (10). The rat virus had been serially passage in laboratory rats. The 
rat liver homogenate was titrated in a bioassay of laboratory rats inoculated with the serial 
dilution of the original liver homogenate and contained a titer of 10^ 50% rat infectious dose 
(RID50) per ml. Enzyme linkage immunosorbent assay (ELISA) with the Sar55 HEV strain 
ORF2 capsid protein as the antigen was used as a marker to confirm HEV infection in the 
rats. Feces collected from pigs used as negative controls and prepared as 10% fecal 
suspension (wt/vol) in sterile phosphate-buffered saline (PBS) served as sham inocula for the 
negative-control. The feces used for sham inocula were confirmed to be free for avian and 
swine HEV RNA by nested RT-PCR. 
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Animals and experimental design. Thirty-six, 6-week-old, specific-pathogen-free 
pigs were used in this study. All pigs were free of swine HEV RNA 
in feces and seronegative to both anti-avian HEV and anti-swine HEV antibodies prior to 
inoculation. The negative-control and avian HEV-inoculated pigs were also tested and found 
to be negative prior to inoculation for avian HEV RNA in feces by avian HEV-specific 
nested RT-PCR. 
The experimental design consisted of 4 groups, including negative-control, rat HEV, 
avian HEV, and swine HEV-inoculated groups. Each group contained nine randomly 
selected pigs. Each group was housed in separate room and confincd in a pen with raised 
wire decks. The inoculation route was intravenous for all 4 groups and was performed on a 
single day. Nine pigs in the negative-control group were inoculated with 1 ml of HEV-free, 
10% fecal suspension. The nine pigs in each of the rat and avian HEV group were randomly 
assigned to 2 sub-groups. In the rat HEV group, six pigs were inoculated with a titer of 10^ 
RID50 of rat HEV inocula and the three remaining pigs served as uninoculated contact 
controls. In the avian HEV group, six pigs were inoculated with 5 X 10^ CID30 of the avian 
HEV inocula and three pigs served as uninoculated contact controls. Nine pigs in the swine 
HEV group were inoculated with 10^ PID50 of the swine HEV. 
All pigs were monitored for clinical signs throughout the study. Rectal temperature 
was recorded every other day through 14 days postinoculation (dpi). Feces and serum 
samples were collected prior to inoculation and weekly postinoculation until the end of the 
experiment on 35 dpi. The samples were tested for the presence of HEV RNA by nested RT-
PCR and anti-avian HEV and anti-swine HEV IgG antibodies by ELISA. Feces were 
collected with a sterile Dacron swab and placed in sterile PBS. Fecal swabs and serum 
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samples were stored at -80° C until tested. Liver and bile samples were also collected from 
all pigs at necropsy and were tested for HEV RNA by nested RT-PCR. Liver was prepared as 
a 10% liver homogenate (wt/vol) by a laboratory blender (Stomacher 80, Seward, U.K.). 
Examination of gross and microscopic lesions. Necropsy was performed at 3 time 
points; 7,21, and 35 dpi. Three pigs from each group were randomly selected for necropsy at 
each time point. In the rat and avian HEV groups, the three pigs for each necropsy comprised 
two inoculated and one contact-control pig. Necropsied pigs were grossly examined and a set 
of tissue samples (liver, gall bladder, mandibular salivary gland, lung, heart, kidney, 
pancreas, spleen, tonsil, lymph nodes [hepatic, tracheobronchial, and mesenteric], stomach, 
duodenum, jejunum, ileum, and colon) were collected and fixed in 10% neutral-buffered 
formalin. Two pieces from each of liver lobes (right lateral, right medial, left lateral, left 
medial, quadrate, and caudate lobes) were collected. All tissues were then processed, 
prepared as microslides, stained with hematoxylin and eosin and examined 
histopathologically. Liver sections were blindly scored as previously described (15). Ten 
hepatic lobules from each lobe were examined. Hepatitis scores ranged from 0 to 4; where 0 
is no inflammation, 1 is 1 to 2 focal lymphoplasmacytic infiltrates per 10 hepatic lobules, 2 is 
3 to 5 focal infiltrates, 3 is 6 to 10 focal infiltrates, and 4 is > 10 focal infiltrates. 
Detection of swine or avian HEV RNA by nested RT-PCR. RNA extraction was 
performed by the modified spin column method (QIAamp; QIAgen, Chatsworth, CA) as 
previously described (1). One hundred-forty p.1 of samples (fecal suspensions, serum 
samples, bile, or liver homogenates) were used for RNA extraction. The RNA extract was 
then immediately used for the reverse transcription reaction and cDNA synthesis by an 
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incubation of the RNA, a reverse primer, and Superscript n reverse transcriptase (Invitrogen) 
at 42° C for 1 h. 
To detect avian HEV RNA, an avian HEV-speciGc nested RT-PCR assay was 
performed as previously described (24). The first-round PCR primers comprised the forward 
primer FAHEVEp [5'- CATCCACCCCTACAAGCATTGAC-3'] and the reverse primer 
RAHEVEp [5'-TACGCAACACATCCCCTGACCT-3']. The second-round primers included 
the forward primer FAHEVEpF [5'-GCCGCTTGGTATGGTTGATTTT-3'] and the reverse 
primer RAHEVEpR [5'-GGCATCCTCAACCGAC ATATAC-3']. The second-round PCR 
reaction produced a PCR product size of 373 base pairs (bp) in length. 
To detect swine HEV RNA, a universal nested RT-PCR assay specific for swine HEV 
was performed as previously described (26). The first-round PCR primers comprised the 
forward primer F1 [5'-AATTATGCC(T)CAGTAC(T)CGG(A)GTTG-3'] and the reverse 
primer R1 [S'-CCCTTA(G)TCC(T)TGCTGA(C)GCATTCTC-3']. The second-round primers 
included the forward primer F2 [5'-GTT(A)ATGCTT(C)TGCATA(T)CATGGCT-3'] and the 
reverse primer R2 [5-AGCCGACGAAATCAATTCTGTC-3']. The expected second-round 
amplified PCR product was 348 bp. The amplified PCR products were examined on 1% 
agarose gel electrophoresis. The PCR products were sequenced to confirm that they were 
indeed avian HEV sequences. 
Detection of anti-HEV immunoglobulin (Ig) G antibodies by ELIS A. To detect 
anti-avian HEV IgG antibodies, a purified truncated avian HEV ORF2 protein expressed in 
Esc/zenc&wz co# was used as the antigen as previously described (25). A purified 55-kDa 
truncated recombinant capsid protein from the Sar55 strain of human HEV was used as the 
antigen to detect the anti-swine or anti-rat HEV IgG antibodies (28, 36). Each serum sample 
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was tested in duplicate. The final optical density (OD) values were an average of the two 
ODs. The cutoff value above 0.2, 0.3 and 0.3 was considered as positive for anti-rat HEV, 
anti-avian HEV and anti-swine HEV IgG antibodies, respectively. Preimmune and 
hyperimmune swine sera were used as negative and positive controls, respectively. 
Statistical analysis. The difference of overall hepatitis lesion scores among 
inoculated groups and for each different dpi was analyzed by Kruskal-Wallis test using a 
commercial software (SAS Institute, Cary, NC). Explanatory variables included inoculated 
groups (nominal variable) and the dpi (ordinal variable). A P value of less than 0.05 was 
considered significant in all analyses. 
Results 
Clinical observation. There was no evidence of clinical disease in pigs in any of the 
inoculated groups (data not shown). 
Gross and microscopic findings. No remarkable gross lesions were observed in any 
of the sham-inoculated or HEV -inoculated groups. Microscopic lesions were confined to the 
liver and are summarized in Table 1 and Figures 1 and 2. Variably severe, multifocal, 
lymphoplasmacytic hepatitis was present in 5 of 9 sham-inoculated, 7 of 9 rat HEV-
inoculated, 7 of 9 avian HEV-inoculated, and 9 of 9 swine HEV-inoculated pigs. Variably 
severe, focal hepatocellular necrosis was detected in the lesions of avian and swine-HEV 
inoculated pigs. There was a significant difference (P < 0.05) in the overall mean hepatitis 
lesion scores. On 7 dpi, the mean hepatitis lesion score of swine HEV-inoculated group was 
significantly (P = 0.03) more severe than those observed on the avian HEV-inoculated group. 
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The inflammatory foci observed in the livers collected from swine HEV-inoculated pigs were 
similar in type but larger than those observed in the other groups. 
Detection of HEV RNA. Results of the nested RT-PCR assays for HEV RNA in 
feces, serum, liver, and bile samples tested are summarized in Table 2. None of the liver and 
bile samples collected from pigs inoculated with sham inocula contained HEV RNA. HEV 
RNA was not detected in fecal samples obtained from pigs inoculated with rat HEV at 0, 7, 
14 or 35 dpi. 
All fecal samples from all pigs inoculated with avian HEV (and contact controls) 
contained HEV RNA beginning on 7 dpi and continuing through 28 dpi. HEV RNA was 
detected in serum samples from avian HEV-inoculated pigs from 7 to 21 dpi. In the avian 
HEV group, HEV RNA was detected in serum samples of 5 (including 3 contact controls), 1 
(a contact control), and 1 (a contact control) pig on 7,14, and 21 dpi, respectively. HEV 
RNA was detected in liver of one pig inoculated with avian HEV necropsied each on 7,21, 
and 35 dpi. HEV RNA was detected in bile from 2 avian HEV-inoculated and I contact 
control pigs on 7 dpi, 1 inoculated pig on 21 dpi, and 1 inoculated and 1 contact control pig 
on 35 dpi. 
PCR products amplified from feces collected from a pig inoculated with avian HEV 
on 7,14, and 21 dpi, and PCR products amplified from bile samples collected from 3 pigs 
inoculated with avian HEV on 7 dpi were sequenced. Sequence analysis confirmed that the 
sequences of the virus recovered from the inoculated pigs aligned with the consensus 
sequence of the prototype avian HEV used as the avian HEV inocula. The analysis also 
revealed multiple nucleotide mutations within the sequences of the PCR products. 
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In the swine HEV group, HEV RNA was found in feces from 4,6, 5, and 1 pig on 7, 
14, 21, and 28 dpi, respectively. HEV RNA was detected in the serum sample of one pig on 
21 dpi. Only one pig was positive on 21 dpi for HEV RNA in the liver, while 2 and 1 pigs 
were positive for HEV RNA in bile samples on 7 dpi and 21 dpi, respectively. 
Detection of anti-HEV antibodies. None of the pigs had anti-HEV antibodies prior 
to inoculation. All pigs in the sham-inoculated group remained seronegative for both anti-
swine and anti-avian HEV antibodies throughout the study. All pigs in the rat HEV group 
also remained seronegative through the duration of the study. 
In the avian HEV group, all 6 pigs (4 inoculated and 2 contact controls) remained 
negative for anti-HEV at 21 dpi. One contact control pig developed anti-HEV by 35 dpi and 
this pig shed avian HEV in feces from 7 to 28 dpi. The seropositive contact-control pig was 
viremic on 7 dpi. On 35 dpi, when the anti-avian HEV seropositive pig was necropsied, HEV 
RNA was detected in the bile; however, liver collected from the pig was negative for HEV 
RNA. 
In the swine HEV group, 2 of 6 pigs developed anti-swine HEV antibodies by 21 dpi 
and those 2 pigs continued to be seropositive on 35 dpi. 
Discussion 
The findings of the present study indicate that avian HEV infects and replicates in 
pigs based on demonstration of HEV RNA in feces, serum, liver, and bile samples of 
experimentally-inoculated pigs. One of the contact control pigs also developed antibodies 
against the avian strain of HEV. 
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Avian HEV recovered from chickens has recently been shown to cross species barrier 
and infect turkeys (42). Avian and swine HEV are genetically distant (25,43); however, 
avian HEV may have ability to adapt to a wide range of host species. The partial sequence 
amplified from feces collected from one infected pig revealed 4 single nucleotide mutations. 
The primers used were designed to target the ORF2 sequence which encodes for capsid 
protein. Thus, the nucleotide mutations may reflect the ability of the virus to readily modify 
its protein envelop to accomodate different receptors in a variety of host species. These 
findings indicate that pigs may be used as a model to study the molecular mechanism of virus 
adaptation to different hosts. Infectious cDNA clones of swine HEV have been demonstrated 
to be infectious in pigs (23). The use of infectious clone of HEV and a swine model that is 
susceptible to multiple strains of HEV should facilitate the comparative study of HEV 
virulence factors and pathogenesis. 
Pigs and chickens are commonly raised in close proximity. Both swine and chicken 
HEV are ubiquitous in their respective host populations (25,26). It is likely that natural 
exposure of pigs to avian HEV and likewise chickens to swine HEV occurs frequently in the 
Geld. Such conditions would provide opportunities for avian HEV to adapt for replication in 
pigs and vice versa. It currently remains unknown if swine HEV is transmissible to chickens. 
Attempts in our preliminary study to transmit the avian HEV to two pigs using 
inocula with a titer of 10* GE via the intravenous route were unsuccessful (data not shown). 
Thus, in the present study we used a higher titer of 5 X 10^ CID50 which is equivalent to 
approximately 10* genome equivalent. Inoculation of rhesus monkeys with a similar titer of 
avian HEV was unsuccessful (24). Dose dependent infection of avian HEV has been 
demonstrated in experimentally-infected chickens (42). 
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The inoculation route in the present study was intravenous, although this 
experimental route is probably unlikely to occur under natural conditions. The intravenous 
route was used because experimental HEV infection via oral inoculation is known to be less 
successful (38). It remains to be determined if avian HEV is transmitted via the fecal-oral 
route as is the case with swine HEV in pigs (29). All avian HEV-inoculated pigs shed the 
virus in feces from 7 to 28 dpi, and contact control pigs in the avian HEV-inoculated group 
became avian HEV-infected. Viremia was detected in 3 contact control pigs by 7 dpi, 1 pig 
by 14, and another on 21 dpi. This suggests that the avian HEV shed by the inoculated pigs 
was infectious and transmission occurred through direct contact. It is likely, but yet to be 
confirmed, that transmission occurred via the fecal-oral route since all pigs in the avian 
HEV-inoculated group shed the virus in feces. However, aerosol or exposure to other body 
secretions such as saliva can not be ruled out under the experimental conditions of this study. 
Avian HEV infection of pigs induced subclinical hepatitis which is similar to what we 
observed in the present and other studies with swine HEV infection (15, 35). The hepatitis 
lesions found in the swine HEV-inoculated pigs were similar in type but slightly more severe 
than those in the avian HEV-inoculated pigs. The mild hepatitis lesions found in the sham-
inoculated and rat HEV-inoculated groups are likely non-specific and not related to HEV. 
This amount of background inflammation in pigs livers is expected (15). There was no 
evidence that these pigs were infected with the porcine circovirus-2 (PCV-2) or porcine 
reproductive and respiratory syndrome virus (PRRSV). Porcine circovirus-associated lesions 
in pigs (granulomatous hepatitis and lymphoid depletion) were not observed in the liver and 
lymphoid tissues in the pigs in this study and PCV-2 antigen was not detected by 
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immunohistochemistry (data not shown). All 12 pigs remained seronegative for PRRSV 
through 35 dpi (data not shown). 
The viremic stage of HEV infection is transient (15). It typically follows the onset of 
virus shedding in feces by 1 week and persists for only 1 to 2 weeks. Only 1 pig in the swine 
HEV group had detectable HEV RNA in the serum sample and this was at 21 dpi. Viremia 
was not detected in pigs transfected with a swine HEV infectious clone (23). This may also 
explain why most pigs in the swine HEV group did not have detectable HEV RNA in serum 
samples that were collected and tested at weekly intervals. 
Hepatitis E virus is thought to replicate in the cytoplasm of hepatocytcs (6, 14, 47). 
The epithelial cells of intrahepatic bile ducts may also support HEV replication (6,14). 
Extrahepatic sites of HEV replication also exist and include the intestines, lymph nodes, 
tonsil, and spleen (6, 47). HEV RNA was found in the liver and bile samples in pigs 
inoculated with avian HEV. Avian HEV RNA was also detected in the liver and bile samples 
in a number of pigs. This may reflect the shift and/or different predilection of tissues that 
avian HEV replicates and might be different from swine HEV. 
Serological evidence suggests that rats may serve as a reservoir of HEV in humans 
(11, 20, 28). In the present study, we attempted to determine if HEV discovered in wild rats 
was infectious to pigs. The pigs in the rat HEV group did not develop detectable levels of 
anti-HEV antibodies. The nest RT-PCR used in the current study failed to detect HEV RNA 
in feces. The primers of the RT-PCR were designed to detect the ORF2 genes of different 
known strains of human and the prototype U.S. swine HEV in genotype 1, 2, and 3 (26). 
However, rat HEV remains to be genetically characterized. It is possible that the genetic 
makeup of HEV in rats is distinctly distant from other U.S. HEV strains and may not be 
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detectable with the primers used in the present study. HEV is genetically clustered according 
to geographical regions (22,26, 27,40,45). Rat HEV found in Nepal was genetically related 
genotype 1 which is a predominant genotype causing epidemics in humans in the country 
(19). It is speculative that rat HEV found in the U.S. possibly belongs to genotype 3 which 
includes the US-2 strain of human HEV and the U.S. swine HEV. 
In past two decades, emerging viral infections have been reported as zoonotic 
epidemics in humans and most of the viruses (i.e. sever acute respiratory syndrome [SARS] 
coronavirus, influenza viruses, or Nipah virus) are RNA viruses (2, 5,21). These emerging 
viruses share a common characteristic of an animal reservoir. Current practices of livestock 
production create favorable conditions for emergence of new viruses and interspecies 
transmission since the animals are often raised in large and dense populations (21) or are kept 
in close contact (5). This type of production may increase the propagation of viruses to large 
numbers, transmission to other hosts in these environments, and prolonged survival and 
circulation to sustain their existence in environments. Mixed multi-species environments (i.e. 
live-poultry markets) have been linked to the emergence of cross-species influenza A 
epidemics between domestic fowl and in-contact humans in Hong Kong (5). In addition, 
increasing contact between humans and animal reservoirs may facilitate cross-species 
transmission from susceptible reservoir species to humans (12). 
Pigs potentially serve as mixing vessels for zoonotic viral diseases as suggested in 
influenza A viruses (2). The role of intermediate hosts between a natural reservoir species 
and humans has been implicated in the recent emergence of SARS coronavirus epidemics 
(5). Viruses replicating in intermediate host species may adapt to augment a range of 
susceptible host species. It remains to be determined if avian HEV becomes more virulent or 
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continues to gain the ability for replication in an extended range of host species following 
sequential passage in susceptible animals such as pigs. 
In summary, we demonstrated that avian HEV was readily transmissible to pigs by 
intravenous inoculation. Avian HEV from inoculated pigs was infectious and readily 
transmitted to uninoculated contact-control pigs. Avian HEV induced subclinical hepatitis in 
pigs and appeared to replicate efficiently in the pigs as HEV RNA was found in feces and 
bile. The genetic sequence of avian HEV following a passage in pigs revealed a number of 
single nucleotide mutations and may reflect adaptability to a new host. This may open new 
avenues of research into the molecular pathogenesis and epidemiology of HEV infection. 
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Table 1. Hepatic lesions in sham, rat, avian, and swine HEV-inoculated pigs 
Group Mean score ± S. D. of hepatitis lesions" 
in pigs (m = j) on the following dpi 
Total mean score 
± S. D. 
7 21 35 
Sham-inoculated 0b 1.00 ±0.00" 0.67 ± 0.58* 0.56 ±0.53* 
Rat HEV -inoculated 1.00 ±0.00* 1.00 ±0.00* 0.33 ±0.58* 0.78 ± 0.44* 
Avian HEV-inoculated 0.67 ± 0.58* 1.00 ±0.00* 0.67 ± 0.58* 0.78 ± 0.44* 
Swine HEV -inoculated 2.00 ± 0.00' 1.00 ±0.00* 1.00 ±0.00* 1.33 ±0.50' 
" Hepatitis lesions characterized by lymphoplasmacytic inflammation; scores: 0 = no 
inflammation, 1 = 1 to 2 focal lymphoplasmacytic infiltrates per 10 hepatic lobules, 2 = 3 to 
5 focal infiltrates per 10 hepatic lobules, 3 = 6 to 10 focal infiltrates per 10 hepatic lobules, 4 
= >10 focal infiltrates per 10 hepatic lobules. 
*"' Values with different supercnpts (6 or c) are significantly different (P < 0.05) from other 
values in the same column. 
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Table 2. HEV RNA in feces, serum, liver, and bile of sham- and HEV-inoculated pigs 
Inocula Sample No. of positive inoculated pigs (no. of positive contact control 
pig) per no. tested on the following dpi; 
0 T 14 21" 28 35= 
Sham 
Feces 0/9 0/9 NT* NT NT 0/3 
Serum NT NT NT NT NT NT 
Liver NT 0/3 NT 0/3 NT 0/3 
Bile NT 0/3 NT 0/3 NT 0/3 
Rat HEV 
Feces 0/9 0/9 0/6 NT NT 0/3 
Serum NT NT NT NT NT NT 
Liver NT NT NT NT NT NT 
Bile NT NT NT NT NT NT 
Avian HEV 
Feces 0/9 6(3)/9 4(2)/6 4(2)/6 2(1X3 0/3 
Serum NT 5(3)/9 l(l)/6 l(l)/6 0/3 0/3 
Liver NT l(0)/3 NT l(0)/3 NT l(0)/3 
Bile NT 2(l)/3 NT l(0)/3 NT l(l)/3 
Swine HEV 
Feces 0/9 4/9 6/6 5/6 1/3 0/3 
Serum NT 0/9 0/6 1/6 0/3 0/3 
Liver NT 0/3 NT 1/3 NT 0/3 
Bile NT 2/3 NT 1/3 NT 0/3 
* dpi on which necropsy was performed. 
*Not tested, samples not collected or tested on this dpi. 
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CHAPTER 8. 
GENERAL CONCLUSIONS 
Swine HEV causes a subclinical hepatitis in growing pigs (27). HEV-infected pigs 
became viremic for a relatively short period of 1 to 2 weeks. The viremia occurs 1 to 3 
weeks postinfection and fecal shedding typically precedes the viremia by 1 week and persists 
for 3 to 6 weeks. The presence of HEV in feces serves as a major source of the virus for 
transmission to contact animals and people and contamination of the environment. 
Following the viremic state, anti-HEV IgG antibodies first appear by 5 weeks postinfection 
and persist for several months. There were no remarkable macroscopic lesions in swine 
HEV-infected pigs. HEV-associated microscopic lesions in growing pigs are characterized 
by mild multifocal lymphoplasmacytic hepatitis with focal hepatocellular necrosis. The 
clinical, virological and histopathological pattern of HEV infection in pregnant adult pigs 
was similar to that reported in growing pigs. 7» wfem transmission did not occur in HEV-
infected pregnant pigs and HEV infection of the dam did not induce evidence of reproductive 
failure or disease or lesions in offspring bom to the HEV-infected pregnant pigs. These 
findings suggest that HEV is probably not responsible for reproductive failure in pigs. 
Piglets that suckled HEV-infected dams acquired anti-HEV IgG antibodies through 
colostrum intake and the passive antibodies waned to undetectable levels by 2 months of age. 
Hepatitis E virus-free pigs were derived by early weaning of the piglets (18 days of age) from 
the dams. This is important information for producers or researchers interested in 
establishing HEV-free pig sources. 
The fecal-oral route appears to be the primary mode of HEV transmission in pigs. 
HEV is readily transmitted through direct contact, although effective transmission apparently 
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requires a high number of infective virus particles and/or repeated exposure via the fecal-oral 
route. Experimental HEV inoculation through the oral route with a single dose of 1CP or 10^ 
GE in a previous study failed to sufficiently induce HEV infection while repeated oral 
inoculation for three consecutive days was sufficient in inducing HEV infection in our 
subsequent study. Transmission via the aerosol route, contaminated needles, or exposure to 
body secretions such as saliva appeared to be unlikely based on the findings of the third 
experiment. 
Liver from pigs in the early stages of HEV infection was found to be a potential 
xenozoonotic threat to transmit HEV. Pigs inoculated intravenously with liver homogenates 
collected from other pigs in the early stages of infection developed HEV infection as 
determined by the presence of HEV viremia and development of anti-HEV antibodies. The 
risk of xenozoonoic HEV infection by using heart or pancreatic tissues from HEV-infected 
pigs is minimal, if it exists at all, since HEV was not detected by the RT-PCR in these tissues 
and the swine bioassay further confirmed that homogenates of heart or pancreas contain no 
detectable or infectious HEV. The RT-PCR used in the first study appears to be a suitable 
and sensitive diagnostic tool to detect HEV-infected livers and thus avoid the risk of 
xenozoonotic transmission via xenotransplantation. 
Growing evidence of HEV as a fbod-bome zoonotic infection has been recently 
documented (54, 83,100). Consumption of raw liver collected from a wild boar caused a 
cluster of HEV infections in Japanese human patients (54). This is in accordance with the 
findings of our swine bioassay where liver collected from HEV-infected pigs contained 
viable virus and was infectious to pigs. Another recent report of an incidence of human HEV 
infection indicates that the consumption of raw meat collected from wild deer may also be 
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responsible for HEV infection (83). In contrast, pork loin collected from pigs during active 
HEV infection was found to be free of detectable HEV. It is possible that the HEV present in 
the deer meat may be due to fecal contamination from the deer or people who handled the 
meat. The pattern of HEV infection in wild deer remains unknown and awaits further 
investigation and characterization. 
HEV is heterogeneic and geographical clusters of heterogeneous genotypes have been 
globally reported (20,40, 71). The results of our fourth study further confirm such 
conclusions. HEV was found in fresh pig feces and from stored pig manure collected from 
concrete pits or earthen lagoons on pig farms in Iowa. The partial genetic sequence analysis 
of HEV amplified by RT-PCR in the study indicated that all HEV isolates in the study 
clustered within the genotype 3 of HEV which is mainly located in North America and 
contains the prototype U.S. swine and human US-2 strain of HEV. These isolates were 
genetically distant from other genotypes of HEV found on other continents of the world. 
HEV isolated from pig feces and from manure in storage facilities on the same farms tended 
to be more closely related to each other than to HEV isolates from different farms. This 
suggests that feces and manure storage facilities (pits and lagoons) may be an important 
source of contamination of naive pigs, other domestic animal species, and the environment 
with HEV. 
The fifth study demonstrated that avian HEV infected and replicated in pigs. HEV 
RNA was detected in the liver, bile and feces of pigs inoculated with avian HEV. One of 3 
inoculated pigs developed IgG antibodies specific to avian HEV ORF2 antigen by 35 dpi. 
The pattern of virus shedding in feces and viremia of avian HEV infection in pigs is similar 
to that induced by swine HEV. Like swine HEV, the avian HEV induced a subclinical 
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hepatitis in pigs and the severity of the microscopic lesions was less severe than observed 
with swine HEV. It is interesting that the nucleotide sequence of the amphcon found in feces 
and bile collected from a pig infected with the avian HEV revealed a few single point 
mutations when compared to the sequence of the original virus in the inocula. The findings 
may reflect the adaptability of avian HEV to replicate in pigs. Although avian HEV may be 
able to cross species barriers to infect pigs, the avian HEV appears to be less likely a 
potential zoonotic infection than the swine HEV since the avian HEV failed to 
experimentally infect rhesus monkeys whereas swine HEV was able to induce infection and 
lesions in nonhuman primates (38, 59). It appears that rat HEV was not capable of infecting 
pigs. None of three rat HEV-inoculated pigs developed anti-HEV IgG antibodies specific to 
genotype 3 HEV strains. 
In summary, HEV causes a subclinical hepatitis in both growing pigs and pregnant 
gilts. Liver and feces from HEV-infected pigs are the primary source of HEV transmission. 
Natural transmission of HEV in pigs is primarily via the fecal-oral route. Liver 
transplantation also poses a risk of HEV transmission in humans. Consumption of uncooked 
pig liver may result in clinical HEV-induced disease in humans. HEV is widespread on pig 
farms and pig manure may be a source of contamination to the environment and for HEV 
transmission. Cross-species infection of pigs with avian HEV has now been demonstrated 
and may open new avenues of research into the molecular pathogenesis and epidemiology of 
HEV. 
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